We’re at the @ACAAI 2026 Annual Scientific Meeting in Phoenix.
New data from our Phase 3 VITESSE study in children ages 4–7 with peanut allergy will be highlighted in three ePosters on Friday.
Join us for our presentations on Friday, 11/13 and our Product Theater on Saturday, 11/14. Visit us at Booth #1524.
Read the release: dbv-technologies.com/press_releases/dbv-technologies-high…
DBV Technologies
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. More on Wikipedia
-
DBV Technologies
@DBVTechnologies
-
DBV Technologies
@DBVTechnologies
This November, we are participating in two investor conferences:
· Guggenheim Securities Healthcare Conference on November 9
· LifeSci Capital X Sofinnova 2026 Growth & Innovation Summit on November 16
We look forward to engaging with investors and industry peers as we continue to advance our food allergy platform.
For details: dbv-technologies.com/press_releases/dbv-technologies-to-p… -
DBV Technologies
@DBVTechnologies
On October 28, we will report our third quarter 2026 financial results and provides a business update.
We will host a conference call and live webcast at 5:00 PM ET on Wednesday, October 28th.
Participants may join the call via telephone:
📞 US & Canada Toll-Free: 877-344-8082 (live operator answer)
📞 US Toll (secondary/backup or international toll): +1- 213-992-4618 (live operator answer)
➡️ Tune in to learn more: event.summitcast.com/view/44hp2DVKg4qChWJ2ijomvj/guest_bo…. The live webcast will also be available on the Events section of our website.
For additional information, read our full press release: dbv-technologies.com/press_releases/dbv-technologies-to-r… -
DBV Technologies
@DBVTechnologies
We're proud to announce the submission of a Biologics License Application (BLA) to the @US_FDA for our investigational treatment option for children ages 4 through 7 with peanut allergy.
Learn more here: dbv-technologies.com/press_releases/dbv-technologies-anno… -
DBV Technologies
@DBVTechnologies
This September, we will be participating in three investor conferences:
➡️ Cantor Fitzgerald Global Healthcare Conference – Fireside Chat on Wednesday, September 9.
➡️ Citi’s 2026 Biopharma Back to School Conference – 1 on 1 Meetings on Thursday, September 10.
➡️ H.C. Wainwright & Co. Global Investment Conference – Fireside Chat on Tuesday, September 15.
We're grateful for these opportunities to engage with investors and industry peers and we look forward to sharing updates on our regulatory and commercial progress.
For details: dbv-technologies.com/press_releases/dbv-technologies-to-p… -
DBV Technologies
@DBVTechnologies
Every day, our team works to change what care could look like for children living with food allergies. Our efforts are grounded in science and shaped by the needs of patients and their families.
Explore opportunities to join us: dbv-technologies.com/careers/ -
DBV Technologies
@DBVTechnologies
For most families, back-to-school season means new supplies and new routines. Managing a child's food allergy means a lot of extra planning: briefing teachers, coordinating with cafeteria staff, packing safe lunches, and reviewing every label, all before the first bell rings.
Peanut allergy in particular can restrict daily activities and create ongoing worry for children and their families, including concerns about school.
At DBV, this is part of why we do what we do — we're committed to advancing options that could potentially help ease this burden.
To every family gearing up for the school year: we see the planning, the vigilance, and the care you put in. We're with you. Learn more about our mission: dbv-technologies.com/about-dbv/ -
DBV Technologies
@DBVTechnologies
This August, we’re heading to three regional allergy conferences:
- New York Allergy & Asthma Society (NYAAS)
- Alabama Society of Allergy, Asthma and Immunology (ASAAI)
- American Society of Allergy Professionals (ASAP)
Through these engagements, we look forward to our continued dialogue with state-level allergy societies as we advance our commitment to addressing the significant unmet medical need in pediatric allergy care.
Visit our booth to learn more! -
DBV Technologies
@DBVTechnologies
At the center of our approach to food allergy management is epicutaneous immunotherapy (EPIT); a differentiated mechanism of action that uses the skin as the entry point for immune modulation.
As the body's largest immunologic organ, the skin plays an important role in shaping immune responses. EPIT harnesses the immune properties of the skin to help induce desensitization while limiting systemic allergen exposure.
At DBV, we’re working to advance this non-invasive and innovative approach to food allergy management, because patients and families deserve more options.
Learn more about our science: dbv-technologies.com/our-science/viaskin-platform/ -
DBV Technologies
@DBVTechnologies
Timing can change everything in food allergy care.
In the earliest years of life, the immune system is remarkably adaptable. This creates a critical window of opportunity when early diagnosis and intervention may help re-educate the immune system before allergic patterns become firmly established.
Peanut allergy often begins in infancy and typically persists throughout life. That’s why continued research in younger children is so important.
At DBV, we’re advancing an innovative approach that harnesses the powerful immune properties of the skin – the body’s largest immunologic organ – to potentially desensitize children to allergens over time.
Evidence has shown the strongest benefit when treatment is started earlier and continued long term.
🔗 Learn more about our science: dbv-technologies.com/our-science/ -
DBV Technologies
@DBVTechnologies
We're looking forward to joining clinicians, researchers, and healthcare leaders in Colorado this week for the 2026 Annual Aspen Allergy Conference.
This meeting provides an important opportunity to connect with experts in the field to discuss the latest advances shaping the future of allergy care.
We're excited to be a part of the conversations around emerging potential treatment options and the continued progress for patients and families living with food allergies.
Learn more about the conference here: education.aaaai.org/rsl/2026aac -
DBV Technologies
@DBVTechnologies
The team behind DBV brings more than scientific expertise; they also bring personal connections to the food allergy community.
Mary Hawkins, Medical Science Liaison at DBV Technologies, was a practicing pediatric allergy nurse before joining our team. The experiences she had with children and families living with food allergies don't just inform her work, they inspire it.
For Mary, and for many of us at DBV, this mission is personal.
Learn more about us here: dbv-technologies.com/about-dbv/ -
DBV Technologies
@DBVTechnologies
Today, we reported our second quarter and half-year 2026 financial results.
These reflect important progress toward our BLA submission for the investigational VIASKIN® Peanut Patch in children 4 through 7 years and advancements across our toddler and infant clinical programs, with funding to support operations and commercial preparedness into Q3 2027.
We remain focused on advancing DBV into its next phase, driven by our commitment to making a meaningful difference for children and families living with food allergies.
Today at 5:00 PM ET, we will host a conference call and live webcast.
Participants may join the call via telephone:
📞United States: +1-877-344-8082
📞International: +1-213-992-4618
The live webcast will also be available on the Events section of our website.➡️Tune in to learn more: dbv-technologies.com/events/q2-quarterly-update/
For additional information, read our full press release: dbv-technologies.com/press_releases/dbv-technologies-repo… -
DBV Technologies
@DBVTechnologies
At DBV, we understand that living with peanut allergy doesn't look the same for everyone. That’s why we’re proud to advance a proactive, patient-centric approach to peanut allergy management that meets patients and families where they are on their journey.
Recently at the @EAACI_HQ Congress 2026, we previewed our newly initiated Phase 2 THRIVE open-label study assessing ad lib consumption of peanut in infants ages 6 through 12 months with peanut allergy treated with epicutaneous immunotherapy.
THRIVE is quintessential DBV. It is a reflection of our commitment to the food allergy community and a bold next step toward meaningful progress, where early intervention may help shape long-term outcomes.
Learn more in our press release: dbv-technologies.com/press_releases/dbv-technologies-to-p… -
DBV Technologies
@DBVTechnologies
This summer, the DBV team went to Camp TAG, hosted by FAACT, a dedicated space where children with food allergies can experience the full joy of summer camp and just be kids; something that can feel out of reach for families navigating strict avoidance every day.
These experiences are a meaningful reminder of the children and families at the heart of our commitment to advance #foodallergy care.
We’re proud to support the organizations helping create safe, welcoming spaces for this community – because life should be bigger than food allergies.
Learn more about our mission: dbv-technologies.com/about-dbv/ -
DBV Technologies
@DBVTechnologies
We are pleased to announce that DBV Technologies has been included in the Euronext Tech Leaders index, recognizing leading business for their innovation, growth trajectory, and contribution to the European technology ecosystem.
We believe this inclusion reflects the strength of our scientific programs and our progress in advancing pediatric #foodallergy care.
Read the full press release to learn more: dbv-technologies.com/press_releases/dbv-technologies-anno… -
DBV Technologies
@DBVTechnologies
Behind every advancement in #foodallergy care are people driven by purpose.
Chalise, Senior Director, Clinical Supply Chain, understands the impact food allergies can have on how children and families navigate the world, and the vigilance they require in everyday life. Joining DBV has deepened her respect for these families and her commitment to bringing them hope.
That perspective fuels a more driven, intentional approach to our work as we advance research that could make a meaningful difference in food allergy care. Learn more about the people behind our mission: dbv-technologies.com/about-dbv/leadership/ -
DBV Technologies
@DBVTechnologies
We look forward to connecting with the food allergy community at @EAACI_HQ Congress 2026, where we will share:
➤ A subgroup analysis of children ages 4 through 7 with peanut allergy and atopic comorbidities from our Phase 3 VITESSE study.
➤ A preview of our newly initiated Phase 2 THRIVE open-label study assessing the ad lib consumption of peanut in infants ages 6 through 12 months with peanut allergy treated with epicutaneous peanut immunotherapy.
Across age groups, we are proud to advance a proactive, patient-centric approach to peanut allergy management that meets patients where they are on their journey.
Read more in our press release: dbv-technologies.com/press_releases/dbv-technologies-to-p… #eaacicongress2026 -
DBV Technologies
@DBVTechnologies
What if your work could help change the future of pediatric food allergy care?
At DBV, our team is fueled by curiosity, strengthened by collaboration, and grounded in scientific credibility.
Together, we are working to imagine a world where food allergies and immunological conditions are treated safely, effectively, and with greater care for children and their families.
Explore opportunities to join us: dbv-technologies.com/careers/ -
DBV Technologies
@DBVTechnologies
A proud moment for our team! We were featured on the @Nasdaq Tower for #foodallergyawarenessweek; a meaningful reminder of the families we aim to serve.
We’re dedicated to advancing pediatric #foodallergy care and supporting our community every step of the way.
Discover more about our mission: dbv-technologies.com #faaw2026 -
DBV Technologies
@DBVTechnologies
Our team is coming together in teal to show support for the food allergy community. Behind our work are people with lived experiences and personal connections, as parents, physicians, advocates, and individuals who understand the impact food allergies can have on everyday life.
We understand firsthand how food allergies may be unseen but should never be unnoticed. Sharing these perspectives is one way we continue to build awareness and strengthen our mission of advancing pediatric #foodallergy care.
Learn more about our team and commitment: dbv-technologies.com/about-dbv/
#faaw2026 -
DBV Technologies
@DBVTechnologies
May is #foodallergyawarenessmonth! For millions of families, food allergy is more than a diagnosis, it is a daily reality that requires constant awareness, preparation, and care. This month, we’re highlighting the importance of education, advocacy, and continued progress in pediatric food allergy care.
At DBV Technologies, we’re proud to work alongside organizations to create a future where children and families can navigate food allergies with confidence.
Learn more from our advocacy partners: @AllergyAsthmaHQ, @AAFA_Advocacy, @FoodAllergy, FAACT and @FoodAllergyCAN. -
DBV Technologies
@DBVTechnologies
Today, we reported first quarter 2026 financial results. Read the full press release here: dbv-technologies.com/press_releases/dbv-technologies-repo…
-
DBV Technologies
@DBVTechnologies
How can a potential #foodallergy treatment harness the powerful immune properties of the skin?
Our VIASKIN® technology platform leverages epicutaneous immunotherapy (EPIT) to potentially desensitize patients to allergens like peanuts and milk by delivering microgram amounts of allergens through intact skin without entering the bloodstream.
Watch the video to learn more: dbv-technologies.com/our-science/ -
DBV Technologies
@DBVTechnologies
#peanutallergy often starts in early childhood and can persist into adulthood. For many families, this means years of daily caution, lifestyle changes, and emotional stress.
We understand that food allergy management can feel overwhelming, and that every person’s journey is unique. That’s why we’re developing options that may allow families to take a more proactive approach to care.
As part of our commitment to the food allergy community and offering solutions to families, regardless of where they are in their journey, we plan to expand our clinical research to include infants aged 6–12 months with peanut allergy in a first-of-its-kind Phase 2 study.
In addition to clinical evidence across age groups, we believe epicutaneous immunotherapy (EPIT) has the potential to modify the trajectory of peanut allergy. Learn more about our technology and approach here: dbv-technologies.com/our-science/ -
DBV Technologies
@DBVTechnologies
Passionate about innovation that makes an impact?
Our team is focused on bringing VIASKIN® – our investigational treatment platform designed to alleviate the burden of #foodallergy care – to children and families.
If you're looking to grow your career while delivering meaningful solutions that make a difference, explore our open roles across the U.S. and France: dbv-technologies.com/careers/ -
DBV Technologies
@DBVTechnologies
In the U.S. alone, peanut allergy affects ~400,000 children between the ages of 4–7.
A significant unmet need remains for more proactive approaches that not only reduce the frequency and severity of allergic reactions but also address existing barriers to care.
VITESSE, our Phase 3 study in peanut-allergic children aged 4–7, evaluated the VIASKIN® Peanut Patch. Recent positive topline results were announced, followed by additional data presented last month.
Subscribe to stay up to date on our latest data and presentations: dbv-technologies.com/investor-overview/news/ -
DBV Technologies
@DBVTechnologies
We’re pleased to report our full year 2025 financial results, reflecting
strong momentum and disciplined execution across clinical
development, regulatory progress, and financial strategy.
We remain on track to submit two separate BLAs in 4-7-year-olds and
1-3-year-olds, in the first half and second half of the year respectively,
progressing toward delivering on our mission to bring new
practical, treatment options to peanut allergic children and their
families
Read the full earnings here: dbv-technologies.com/press_releases/dbv-technologies-repo… -
DBV Technologies
@DBVTechnologies
We are proud to share that DBV Technologies is joining France's CAC Mid 60 and SBF 120 indices following the Euronext Paris' 2026 annual review.
This global recognition reflects our growing momentum and continued progress toward our long-term vision to advance pediatric #foodallergy care.
Read the full press release to learn more: dbv-technologies.com/press_releases/dbv-technologies-to-j… -
DBV Technologies
@DBVTechnologies
#foodallergy management is a journey that evolves throughout childhood. At DBV, we aim to advance solutions that meet families where they are on their journey.
Our investigational #peanutallergy patch is designed to engage the immune system and build sustained tolerance that lasts over time.
Over 1.1 million patches have been administered to more than 1,600 children ages 1 to 7 across our clinical programs.
Driven by a commitment to developing a treatment for food allergy, we continue to push progress forward with ongoing research across multiple age groups.
Learn more about our current pediatric #peanutallergy safety study in toddlers aged 1-3 here: comfort-toddlers-study.com/learnmore/ -
DBV Technologies
@DBVTechnologies
At DBV, our culture is grounded in our Four Cs, the values that shape how we work and why we do what we do to advance #foodallergy research for children and families.
In this employee spotlight, find out which “C” resonates the most with Jennifer Meunier, our Internal Communications Project Manager, and what it means at DBV.
If our values speak to you, we invite you to explore opportunities to join our team and help move our mission forward: dbv-technologies.com/careers/
#dbvteam -
DBV Technologies
@DBVTechnologies
We’re looking forward to connecting with leaders across the healthcare landscape next week:
1️⃣The Citizens Life Sciences Conference, where we will participate in a #firesidechat on March 10.
2️⃣ The Leerink Partners Global Healthcare Conference, where members of our leadership team will host 1-on-1 meetings.
We welcome these opportunities to connect with industry peers and the investor community to share insights on recent company progress as we continue advancing our investigational treatment option for pediatric #peanutallergy.
To watch a live webcast of the Fireside Chat at Citizens, register here: event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/guest_bo…
The presentation will also be available on the Events section of our website. Learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p… -
DBV Technologies
@DBVTechnologies
Today, we presented at the 2026 @AAAAI_org Annual Meeting!
Swipe through data highlights and expert insights and from our:
📍Oral Abstract Presentation, where David Fleischer, MD, shared additional positive results from the successful VITESSE Phase 3 study in peanut-allergic children aged 4-7 years, including clinically meaningful changes in reaction threshold.
Read our full data release to learn more: dbv-technologies.com/press_releases/dbv-technologies-high… #aaaai26 -
DBV Technologies
@DBVTechnologies
Allergic reactions are unpredictable; accidental exposures can still occur despite best efforts to avoid them. For many families, avoidance alone may not be enough.
There remains a real need for proactive approaches that not only reduce the risk and severity of allergic reactions but also address the barriers to care that exists with current therapies.
In this @ContempPEDS article, Dr. Fleischer, Global Principal Investigator of our VITESSE study in children 4-7 with #peanutallergy, highlights an important distinction: our investigational treatment delivers microgram amounts of peanut protein through intact skin, offering families a non-invasive approach to treatment without having to ingest the allergen.
Learn more: www.contemporarypediatrics.com/view/david-fleischer-md-di… -
DBV Technologies
@DBVTechnologies
This month, our teams across the U.S. and France came together to connect and reflect on our progress to strengthen the partnerships that help us move forward. These moments reinforce how collaboration drives our work to advance food allergy research and potential solutions for children and families.
Behind every milestone is a global team united by purpose, innovation, and an unwavering commitment to the #foodallergy community. -
DBV Technologies
@DBVTechnologies
We look forward to participating at the upcoming 2026 @AAAAI_org Annual Meeting, where we will share insights and results reflecting continued progress in our investigational treatment for children and toddlers with #peanutallergy.
Find details on our oral abstract presentation, product theater, and company booth here: dbv-technologies.com/press_releases/dbv-technologies-to-p…
#aaaai26 -
DBV Technologies
@DBVTechnologies
Valentine’s Day is just around the corner! While many parents, teachers and students look forward to sharing sweet treats on this fun holiday, classroom celebrations can create heightened risk for accidental allergen exposure.
At DBV, we understand that this can bring added stress for families and children managing #foodallergies. Learn how we’re working to help reduce the risk and severity of accidental exposure reactions: dbv-technologies.com -
DBV Technologies
@DBVTechnologies
More children in the U.S. are living with #peanutallergy than ever before, and the increasing prevalence has driven a growing need for more accessible, safe and effective treatment options.
The COMFORT Toddlers clinical trial, a supplemental safety study evaluating our investigational treatment option in toddlers aged 1-3 years with peanut allergy, is advancing research to address this critical gap in care.
Our innovative technology based on epicutaneous immunotherapy is being developed as a non-invasive, potentially disease-modifying approach to desensitization. Uniquely designed with the needs of young children in mind, it aims to re-educate the immune system and protect from accidental exposure reactions.
In our latest research spotlight, principal investigators from participating COMFORT Toddlers clinical trial sites highlight the ongoing work to offer a potential treatment option that could benefit families and allergists alike. To learn more about our ongoing trial, visit: comfort-toddlers-study.com/learnmore/ -
DBV Technologies
@DBVTechnologies
During our recent investor call, our CEO, Daniel Tassé, shared why the positive topline results from VITESSE, our Phase 3 study in peanut-allergic children aged 4–7 years, represent a pivotal moment in our work to advance #peanutallergy care.
The discussion focused on how these results pave a clear regulatory pathway to FDA submission in 1H26 for our investigational, non-invasive treatment designed specifically with children and families in mind.
Watch the replay here to learn more: event.summitcast.com/view/m86S5JL72DFHJmhtswnPao/eh9nKU5q… -
DBV Technologies
@DBVTechnologies
We’re pleased to announce €166.7 million in gross proceeds following the full exercise of the ABSA warrants and BS warrants issued on our March 2025 financing.
With this capital, we are sufficiently funded to support operations and commercial preparedness to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved.
Learn more: dbv-technologies.com/press_releases/dbv-technologies-anno… -
DBV Technologies
@DBVTechnologies
We’re proud to be recognized among @SnackSafely’s Ten Food Allergy Research Breakthroughs of 2025, underscoring the significance of recent positive topline results from our Phase 3 VITESSE trial in peanut-allergic children ages 4-7.
Learn more👉 snacksafely.com/2025/12/dbv-to-submit-fda-application-aft… -
DBV Technologies
@DBVTechnologies
We’ll be in San Francisco during #jpm2026, attending the LifeSci Partners Corporate Access Event from January 12-14.
Members of our leadership team will share insights on recent company progress, including positive topline results from our Phase 3 VITESSE trial in peanut-allergic children aged 4-7 years, and discuss what’s ahead for DBV in 2026.
We look forward to connecting with global industry leaders and the healthcare investment community. Get in touch to learn more and subscribe to stay up to date on DBV news:🔗 dbv-technologies.com/contact-us/ -
DBV Technologies
@DBVTechnologies
Happy Holidays from the DBV team!
2025 has been a year of meaningful milestones and scientific progress. As we look ahead to 2026, we’re energized by momentum, gratitude, and a continued commitment to advancing safe and innovative potential treatment options for the #foodallergy community.
Thank you to our employees, partners, and the families we serve for your support and trust. Here’s to continuing the journey together. -
DBV Technologies
@DBVTechnologies
Check out the highlights from our Phase 3 VITESSE trial of VIASKIN® Peanut patch, with recent positive topline results in peanut-allergic children aged 4-7 years.
This robust clinical evidence from the largest immunotherapy trial ever conducted in this patient population paves a clear pathway to BLA submission in 1H26, and underscores the potential for a new treatment option for the nearly 400,000 children living with peanut allergy, if approved.
Learn more: dbv-technologies.com/press_releases/dbv-technologies-anno… -
DBV Technologies
@DBVTechnologies
We’re thrilled to share positive topline data from the VITESSE Phase 3 study of VIASKIN® Peanut patch in peanut allergic children aged 4–7. With this important milestone, our planned BLA submission is on track for the first half of 2026.
We extend our gratitude to the participating families, investigators, and their teams for their commitment and partnership as we work to advance this potential, non-invasive treatment.
Join our conference call today at 5pm ET and read the release to learn more: dbv-technologies.com/press_releases/dbv-technologies-anno… -
DBV Technologies
@DBVTechnologies
For families living with #foodallergies, even simple daily activities require thoughtful planning and constant vigilance, from reading every food label to preparing for the risk of accidental exposure.
At DBV Technologies, we’re committed to offering families a safe, effective, and accessible treatment option to help protect them from accidental exposure reactions. Our work is driven by the realities families face every day and the need for innovative approaches in food allergy management.
Learn more: dbv-technologies.com/our-science/ -
DBV Technologies
@DBVTechnologies
At DBV, we’re proud to spotlight the culture that drives our commitment to making a difference for families living with #foodallergies and other immunological diseases.
In our latest spotlight, Robert Pietrusko, Chief Regulatory Officer, reflects on what working toward a potential treatment option for food allergies means to him. The shared purpose and dedication of our team is what propels us forward and inspires how we show up every day.
To learn more, check out our careers page and explore current job openings here: dbv-technologies.com/careers/ #teamdbv -
DBV Technologies
@DBVTechnologies
#icymi, catch up on recent headlines featuring end-of-study data on the long-term efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers, and our planned Phase 2 study in infants with #peanutallergy.
Pieces by @HealthDay, @Allergic Living, and @GoHealio cover insights on the study results presented at @ACAAI 2025 and what the findings may mean for the future of pediatric #foodallergy care.
Stay in the know with more like this from DBV and subscribe for the latest updates, news, and scientific progress: dbv-technologies.com/investor-overview/news/ -
DBV Technologies
@DBVTechnologies
Happy Thanksgiving from the DBV Technologies team! As families gather this season, we’re reminded of the importance of inclusion and awareness for those living with food allergies. At DBV, we remain committed to advancing early intervention and supporting the food allergy community year-round.
Learn how to make your holiday safer and more inclusive: www.foodallergy.org/resources/tips-and-takeaways-your-tea… -
DBV Technologies
@DBVTechnologies
#dyk? Roughly 75% of peanut-allergic children will never outgrow their allergy in their lifetime, leaving millions of families searching for solutions.
At DBV Technologies, we understand that early action may impact food allergy outcomes – that’s why we are focused on advancing care for young children in two key age groups; 1-3 years and 4-7 years.
By supporting early intervention and developing innovative approaches for food allergy management, we aim to improve outcomes for children and families every step of the way. Learn more: dbv-technologies.com -
DBV Technologies
@DBVTechnologies
Calling all peanut allergy families 📢 we want to hear from you!
We’re looking for passionate patients and caregivers in the #foodallergy community to share their experiences with #peanutallergy.
Together, we can help raise awareness, drive change, and support families facing similar challenges. Your voice matters! Fill out the form today: form.jotform.com/252317590128052 -
DBV Technologies
@DBVTechnologies
It was great to be part of the #acaai2025 Annual Scientific Meeting! Our team had the opportunity to connect with the allergy community, engage in thoughtful discussions about the benefits of early intervention, and share insights on how we’re advancing pediatric #foodallergy care. These conversations are what drive the field forward.
Thank you to everyone who joined us at our booth, product theater or poster presentation. #icymi, learn more about our participation at this year’s meeting here: dbv-technologies.com/press_releases/dbv-technologies-to-p… -
DBV Technologies
@DBVTechnologies
Are you attending the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston next week? Our CEO, Daniel Tassé, will participate in a #firesidechat on Tuesday, November 11, at 2:00 p.m. ET
View presentation details to learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p… -
DBV Technologies
@DBVTechnologies
Welcome Kevin Trapp, our Chief Commercial Officer! In his new role, Kevin will lead all aspects of DBV’s global commercial strategy and execution, supporting the company’s mission to advance innovative solutions for the food allergy community.
Learn more about Kevin here: -
DBV Technologies
@DBVTechnologies
We’re thrilled to announce the appointment of Philina Lee to our Board of Directors. Her proven record of leading high-growth organizations through commercialization is invaluable at this stage of DBV’s evolution.
Learn more about Philina here: dbv-technologies.com/press_releases/dbv-technologies-anno… -
DBV Technologies
@DBVTechnologies
We’re excited to participate in the @ACAAI Annual Scientific Meeting and share new insights in pediatric food allergy care.
Connect with us at:
📍Our product theater on the benefits of earlier intervention, where we’ll announce a planned Phase 2 study in peanut-allergic infants.
📍Our oral presentation on the long-term efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers.
📍Our booth, where you can meet with our team and learn more about our investigational treatment option for #peanutallergy.
Meetings like this allow us to drive innovation and collaborate with experts to address unmet needs in food allergy care. Read our full press release for more details: dbv-technologies.com/press_releases/dbv-technologies-to-p… -
DBV Technologies
@DBVTechnologies
Today, we reported third quarter 2025 financial results. Read the full press release here: dbv-technologies.com/press_releases/dbv-technologies-repo…
-
DBV Technologies
@DBVTechnologies
We’re heading to the #fare Food Allergy Summit in Washington D.C.!
From October 30 – November 1, #octoberfare brings together the annual FARE Food Allergy Summit, FARE Neighborhoods Day, and Clinical Development Day, plus a special Teal Pumpkin Halloween Bash for #fare’s #tealpumpkinproject.
We look forward to connecting with peers, advocates and families dedicated to advancing #foodallergy care and driving meaningful change for the community.
Learn more from @FoodAllergy: www.foodallergy.org/take-action/food-allergy-summit -
DBV Technologies
@DBVTechnologies
#dyk, allergic reactions to peanuts and tree nuts spike as much as 85% on Halloween? With 1 in 13 children living with #foodallergies, we all have a role in keeping trick-or-treaters safe.
Thoughtful planning and preparation can lower risks and help families feel secure. At DBV Technologies, we’re committed to advancing a potential treatment option to reduce the seriousness of accidental exposure reactions.
Learn more here: dbv-technologies.com/our-science/ -
DBV Technologies
@DBVTechnologies
At DBV Technologies, we’re working to develop a non-invasive, disease modifying approach to #peanutallergy based on epicutaneous immunotherapy (EPIT).
Our goal is to re-educate the immune system to reduce the risk of accidental exposure reactions. Learn more: -
DBV Technologies
@DBVTechnologies
We’re excited to be at the FAACT Allergy Summit this week in Oak Brook, IL! This event brings together allergy advocates, influencers, patients, caregivers and organizations all committed to advancing care and support for the #foodallergy community.
We look forward to being a part of the conversation. Explore conference details and register here: www.foodallergyawareness.org/faact-allergy-summit/faact-a… -
DBV Technologies
@DBVTechnologies
At DBV, our company culture is built on four core values that we call the 4C’s: Curiosity, Courage, Collaboration, and Credibility.
In this employee spotlight, team members share which “C” resonates most with them and why. This week, we’re highlighting Jessica Raiz, Vice President of Clinical Operations, who connects most with Courage – a value that’s about taking smart risks, mentoring others, pushing boundaries, and turning challenges into opportunities.
Rooted in our DNA, these values guide us in our mission to improving the lives of families affected by #foodallergies and other immunological diseases.
Which “C” resonates the most with you? Explore our careers page to learn more and check out our current job openings: dbv-technologies.com/careers/ -
DBV Technologies
@DBVTechnologies
In recent open-label extension studies evaluating our investigational lead product candidate, sustained treatment showed continued increases in treatment effect over three years.
These results highlight the potential of a gradual approach to progressive desensitization, where continued treatment may lead to stronger outcomes for children and toddlers living with #foodallergies.
View the poster to learn more: dbv-technologies.com/wp-content/uploads/2025/09/DBV253829… -
DBV Technologies
@DBVTechnologies
Our CEO, Daniel Tassé, will be in New York for the H.C. Wainwright 27th Annual Global Investment Conference, where he will participate in a #firesidechat on Tuesday, September 9 at 11:30am ET.
We look forward to engaging with investors and industry peers as we continue advancing our mission to transform #foodallergy treatment. Access presentation details to learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p… -
DBV Technologies
@DBVTechnologies
Teachers, parents and caregivers: Are you ready for students heading back to school? Take our quick quiz to test your knowledge on #foodallergies in the classroom. Education and awareness make all the difference!
-
DBV Technologies
@DBVTechnologies
Clinical trials play a crucial role in expanding what we know about #foodallergy care in young children, where treatment options remain limited.
Right now, important research is being conducted at clinical trial sites across the globe for COMFORT Toddlers, a supplemental safety study evaluating our investigational treatment option in toddlers aged 1-3 years with #peanutallergy.
Our innovative, non-invasive technology based on epicutaneous immunotherapy (EPIT) may offer a promising new way to re-educate the immune system of young children with peanut allergy.
In this spotlight, several of the study's principal investigators share their perspective on what doctors and caregivers are looking for in future treatment options, and why continued research in this space is critical to unlocking safer, more accessible solutions for patients and their families. To learn more about our ongoing clinical trial, visit: comfort-toddlers-study.com/learnmore/ -
DBV Technologies
@DBVTechnologies
As #foodallergies continue to rise each year, especially among children, back-to-school season can bring added stress for families.
Whether your child is heading to daycare, elementary school, or beyond, preparation is key. From allergy action plans to educating school staff, creating a safe, inclusive learning environment takes teamwork and preparation.
Explore downloadable checklists and helpful resources from FAACT (Food Allergy & Anaphylaxis Connection Team): www.foodallergyawareness.org/education-in-schools/food-al… -
DBV Technologies
@DBVTechnologies
We’re #hiring!
At DBV Technologies, our work is grounded in research and fueled by a shared commitment to improving the lives of children and families affected by food allergies and other immunological diseases.
Join our growing team and explore opportunities with us today: -
DBV Technologies
@DBVTechnologies
The DBV team is in Florida for two conferences this week:
1️⃣ The Association of PAs in Allergy, Asthma & Immunology Annual CME Conference from July 31 – August 3 #apaaai2025
2️⃣ The Florida Allergy, Asthma, and Immunology Society 2025 Annual Meeting from August 1-3 #faais2025 @FL_AllergySoc
We welcome the opportunities to connect and look forward to sharing the latest from DBV as we continue progressing toward a potential treatment option for children and toddlers with #peanutallergy. Visit our booths to learn more! -
DBV Technologies
@DBVTechnologies
Teaching #foodallergy safety starts early — and it can be fun, too! Infants, toddlers, and preschoolers are full of curiosity. When food allergies are part of their world, it’s essential to guide them with clear, age-appropriate messages they can remember and repeat to be allergy aware.
“STOP. LOOK. ASK. GO.” is a simple reminder for children to STOP before they eat, LOOK at the food, ASK an adult if it’s ok, and GO if the adult says so. See it in action and watch this video from Center for Food Allergy and Asthma Research (@cfaarnu): www.youtube.com/watch?v=h0Z7aa6-xys -
DBV Technologies
@DBVTechnologies
Today, we reported second quarter and half-year 2025 financial results. Read the full press release here: dbv-technologies.com/press_releases/dbv-technologies-repo…
-
DBV Technologies
@DBVTechnologies
#icymi @SnackSafely spotlighted the initiation of COMFORT Toddlers, our supplementary safety study evaluating our investigational treatment option in peanut-allergic toddlers aged 1-3 years.
Read more about the ongoing study and what it means for families seeking new options for toddlers in this age group living with #peanutallergy: snacksafely.com/2025/06/optimism-grows-for-toddlers-with-… -
DBV Technologies
@DBVTechnologies
We’re headed to Colorado for the Aspen Allergy Conference July 23-27! We look forward to connecting with peers to discuss advancements for the #foodallergy community.
Stop by our booth for the latest on our investigational treatment option for children and toddlers with #peanutallergy and learn more about our ongoing clinical trials.
Explore conference details here: www.aspenallergy.org/program #aspenallergy2025 -
DBV Technologies
@DBVTechnologies
We are pleased to welcome James Briggs as our Chief Human Resources Officer! In his new role, James will lead human capital strategy and organizational development – mobilizing talent, driving operational excellence, and supporting our continued growth. Learn more about James here: dbv-technologies.com/press_releases/dbv-technologies-anno…
-
DBV Technologies
@DBVTechnologies
#dyk? Despite best efforts and careful planning, about 41% of peanut-allergic children experience accidental exposure reactions within three years of diagnosis. For many families, avoidance is not enough.
While immunotherapy can help retrain the immune system, current options like oral immunotherapy (OIT) involve daily peanut doses and complex regimens. Many families are looking for alternatives that offer more flexibility and peace of mind.
That’s why at DBV Technologies, we’re working to expand treatment options through epicutaneous immunotherapy to offer potential protection beyond avoidance alone. Discover how it works: dbv-technologies.com/our-science/viaskin-platform/ -
DBV Technologies
@DBVTechnologies
We’re joining allergy professionals in Park City for the Intermountain West Allergy Association (IWAA) Annual Meeting July 17–19!
Stop by our booth to learn more about our novel, non-invasive approach to #foodallergy treatment with epicutaneous #immunotherapy and discover how we’re shaping the future of food allergy care.
Get the details here: iwaa.org/program/ #iwaa2025 -
DBV Technologies
@DBVTechnologies
We’re in Chicago for the Center for Food Allergy & Asthma Research 2025 CFAAR Food Allergy Summit! We look forward to connecting with clinicians, researchers and advocates driving innovation in the space. Stop by our booth to learn how we’re working to advance new solutions for #foodallergy care.
Explore conference details here: www.feinberg.northwestern.edu/sites/cfaar/events/index.html #cfaar2025 @cfaarnu -
DBV Technologies
@DBVTechnologies
#icymi, two of our Phase 3 clinical trials were recently presented at this year’s Eastern Allergy Conference. Highlights include results from the PEOPLE study, demonstrating the efficacy and safety of long-term epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4–7, as well as the trial design of COMFORT Toddlers, our supplemental safety study in peanut-allergic toddlers aged 1–3.
Explore our Scientific Publications & Presentations page on our website to learn more: dbv-technologies.com/our-science/scientific-publications-… #eac2025 -
DBV Technologies
@DBVTechnologies
We’re pleased to announce that the first subject has been screened in COMFORT Toddlers, a supplemental safety study evaluating VIASKIN® Peanut patch, an investigational treatment option, in peanut-allergic toddlers aged 1–3 years. The data will support a BLA submission under the Accelerated Approval Pathway, as previously agreed to with FDA.
Read the release to learn more: dbv-technologies.com/press_releases/dbv-technologies-anno… #peanutallergy -
DBV Technologies
@DBVTechnologies
We’re off to the #eaacicongress2025 in Glasgow, UK! We look forward to presenting new clinical data on #foodallergy treatment and diagnosis, including data from year two of the EPITOPE Phase 3 extension study on the potential real-world effects of our investigational treatment option in peanut-allergic toddlers, as well as Phase 2 results from the APTITUDE study for diagnosis of non-IgE-mediated cow’s milk allergy in infants.
We’re also hosting a scientific symposium on #peanutallergy where experts and community leaders will explore the allergist-patient relationship and share emerging insights from the field.
Don’t miss out! Read the release for presentation details and visit our booth to learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p… @EAACI_HQ #eaaci2025 -
DBV Technologies
@DBVTechnologies
As Food Allergy Awareness Month comes to a close, we’re proud to stand with the food allergy community – advocating for greater awareness, advancing research, and supporting families and caregivers. At DBV Technologies, our commitment doesn’t end in May – we remain focused on delivering new solutions for those living with food allergies. Together, we’re building a future of greater understanding and hope. #foodallergyawarenessmonth
-
DBV Technologies
@DBVTechnologies
At DBV Technologies, we’re pioneering a novel approach to #foodallergy treatment with our platform technology. By delivering tiny amounts of allergen through the skin, we aim to safely re-educate the immune system and help reduce allergic reactions. Learn more about our non-invasive approach and technology here: dbv-technologies.com/our-science/
-
DBV Technologies
@DBVTechnologies
🤔 Myth or Fact? If a food doesn’t typically contain an allergen, or if the allergen is not listed on the label, it’s safe to eat.
Myth! #foodallergens can appear in unexpected places. This #foodallergyawarenessweek, we’re raising awareness about the importance of reading food labels for those managing life with #foodallergies. Learn how to spot potential allergens and find out exactly what to look for on food labels with resources from @FoodAllergy Research & Education (FARE): www.foodallergy.org/resources/how-read-food-label #faaw -
DBV Technologies
@DBVTechnologies
This Food Allergy Awareness Week, we were featured on the @Nasdaq Tower in Times Square. Seeing our mission lit up in the heart of New York City is a powerful reflection of our ongoing commitment to the #foodallergy community. As we continue working to improve the lives of the millions of children, families, and caregivers affected by food allergies, we’re honored to help raise awareness on this global stage. Learn more about us here: dbv-technologies.com #faaw
-
DBV Technologies
@DBVTechnologies
#dyk? More than 60% of food allergy reactions at school happen in preschools and child care facilities, putting our youngest students at the highest risk. During #foodallergyawarenessweek, staying informed is key to making a difference and creating safer environments. Join us in raising awareness and learn more about #foodallergies in early childhood from @FoodAllergy (Food Allergy Research & Education – FARE): www.foodallergy.org/resources/food-allergies-early-childhood #faaw
-
DBV Technologies
@DBVTechnologies
🌟May is #foodallergyawarenessmonth🌟At DBV Technologies, we remain steadfast in our commitment to improving the lives of children and families affected by food allergies. This month, we’re proud to spotlight the #foodallergy community and our advocacy partners who are driving awareness and making a real impact – thank you for your ongoing support and collaboration!
Learn more from: @AllergyAsthmaHQ (Allergy & Asthma Network), @AAFA_Advocacy (Asthma & Allergy Foundation of America), @FoodAllergy (Food Allergy Research & Education – FARE), FAACT (Food Allergy & Anaphylaxis Connection Team), and @FoodAllergyCAN (Food Allergy Canada) -
DBV Technologies
@DBVTechnologies
A #foodallergy diagnosis can be overwhelming for a child. Involving them early and clearly communicating what’s safe, what’s not, and how to stay protected is key to helping them navigate daily life and manage their food allergy with confidence. Explore more helpful tips from FARE (@FoodAllergy) on how to talk to your child about their food allergy: www.foodallergy.org/resources/talking-children-about-thei…
-
DBV Technologies
@DBVTechnologies
We’re pleased to share new research published in @AnnalsAllergy from the EPITOPE Phase 3 study, highlighting our investigational treatment option after 12 months in children with #peanutallergy – including those with atopic comorbidities. Read the full manuscript to learn more:
-
DBV Technologies
@DBVTechnologies
#icymi, long-term results from our Phase 3 REALISE study were featured in @HCPLiveNews, highlighting the favorable safety profile of epicutaneous immunotherapy (EPIT) with our investigational treatment for children with #peanutallergy. Read the article to learn how these findings underscore the need for more treatment options that balance risk, benefit, and impact on daily life: www.hcplive.com/view/epicutaneous-immunotherapy-shows-fav…
-
DBV Technologies
@DBVTechnologies
Our team is headed to two conferences this week!
1️⃣The Texas, Allergy, Asthma & Immunology Society 2025 Annual Meeting (@TAAIS_tx)
2️⃣The 4th Annual Meeting of the Ohio Allergy and Immunology Society (OAIS)
If you’re attending #taais or #oais, visit our booth to hear the latest from DBV as we continue advancing toward delivering a potential treatment option for children and toddlers with #peanutallergy. We hope to see you there! -
DBV Technologies
@DBVTechnologies
At DBV Technologies, we are on a mission to advance epicutaneous immunotherapy (EPIT) – a potential new class of immunotherapy designed to re-educate the immune system through the skin. Our goal is to develop safe and effective treatment options for #foodallergies and other immunologic diseases with high unmet need. Learn more about us here: dbv-technologies.com/about-dbv/
-
DBV Technologies
@DBVTechnologies
#icymi, we presented long-term data from the Phase 3 PEOPLE Study at the @AAAAI_org / @worldallergy joint congress, including the efficacy and safety of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4-11 years. Access the abstract here to learn more:
-
DBV Technologies
@DBVTechnologies
We are pleased to announce a financing of up to $306.9 Million upfront to advance Viaskin® Peanut Patch for #peanutallergy through a Biologic License Application (BLA) submission and U.S. commercial launch, if approved. Join our investor conference call on Monday, 3/31 at 5pm ET and read the release to learn more: dbv-technologies.com/press_releases/dbv-technologies-anno…
-
DBV Technologies
@DBVTechnologies
This week, we’re attending @ACAAI’s Inaugural Cherry Blossom Allergy Conference. We look forward to engaging with peers on the latest advancements in #allergy research, including our ongoing work at DBV. Stop by our booth to learn more! See conference details here: education.acaai.org/cbac25 #cbac
-
DBV Technologies
@DBVTechnologies
Clinical evidence from the Phase 3 REALISE Study evaluating the long-term safety profile of our investigational treatment option in children with #peanutallergy was published in The Journal of Allergy and Clinical Immunology: In Practice (@jacionline). Read the peer-reviewed article to learn more: www.jaci-inpractice.org/article/S2213-2198(25)00196-5/ful…
-
DBV Technologies
@DBVTechnologies
We are delighted to announce that the U.S. Food and Drug Administration (FDA) has agreed that the safety exposure data from the VITESSE Phase 3 study and the Open-Label Extension will be sufficient to support a Biologic License Application (BLA) of our investigational treatment option in 4–7-year-olds with #peanutallergy, accelerating the timeline for a BLA filing to 1H2026. Learn more here and see our 2024 financial results: dbv-technologies.com/press_releases/dbv-technologies-secu…
-
DBV Technologies
@DBVTechnologies
We’re pleased to share that The Journal of Allergy and Clinical Immunology: In Practice (@jacionline) published an assessment from the first year of our Phase 3 EPITOPE extension study evaluating epicutaneous immunotherapy in peanut-allergic toddlers. Read the peer-reviewed article to learn more: www.jaci-inpractice.org/article/S2213-2198(25)00166-7/ful…
-
DBV Technologies
@DBVTechnologies
#dyk? March is #nationalnutritionmonth! For those living with #foodallergies, nutrition isn’t just about health – it’s about safety and inclusion. At DBV, we’re committed to advancing an investigational treatment option that addresses the needs of young children and families affected by food allergies. Learn more about the importance of nutrition and join us in raising awareness: www.eatright.org/about-national-nutrition-month
-
DBV Technologies
@DBVTechnologies
Today, we’re heading off to the Allergy, Asthma, and Immunology Society of South Carolina Annual Meeting! Visit our booth to explore how we’re advancing an investigational treatment option for children and toddlers with #peanutallergy. For conference details: scallergists.com/meetings-2/ #aaissc
-
DBV Technologies
@DBVTechnologies
On Day 4 of the @AAAAI_org and @worldallergy joint congress, don’t miss our oral abstract presentation by Dr. David Fleischer on the end-of-study efficacy and safety results from the Phase 3 PEOPLE Study in peanut-allergic children aged 4-11 years. See here for presentation highlights and details: dbv-technologies.com/press_releases/dbv-technologies-to-p… #aaaai25 #wao #wac2025
-
DBV Technologies
@DBVTechnologies
On Day 2 of the @AAAAI_org and @worldallergy joint congress, we are hosting a non-CME #producttheater on the key attributes of epicutaneous immunotherapy. Join today for expert insights from Professors Hugh Sampson, MD, Helen Brough, MBBS, PhD, and moderator Douglas Mack, MSc, MD. For details: dbv-technologies.com/press_releases/dbv-technologies-to-p… #aaaai25 #wao #wac2025
-
DBV Technologies
@DBVTechnologies
Come visit our booth (#1740) at the American Academy of Allergy Asthma & Immunology (@AAAAI_org) and World Allergy Organization (@worldallergy) joint congress starting tomorrow! Learn about our work in developing a potential treatment option for peanut-allergic children, including ongoing and planned clinical trials. For details: dbv-technologies.com/press_releases/dbv-technologies-to-p… #aaaai25 #wao #wac2025
-
DBV Technologies
@DBVTechnologies
Our mission is to advance care through innovation. We’re exploring the potential of epicutaneous immunotherapy (EPIT) to enhance treatment options for immunologic diseases, prioritizing the needs of patients and their families. Learn more: dbv-technologies.com/about-dbv/
-
DBV Technologies
@DBVTechnologies
At this year’s American Academy of Allergy Asthma & Immunology (@AAAAI_org) and World Allergy Organization (@worldallergy) joint congress, we will be presenting the latest data and ongoing developments to further advance our investigational treatment option for children and toddlers with #peanutallergy. Learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p… #aaaai25 #wao #wac2025
-
DBV Technologies
@DBVTechnologies
#icymi, our CMO, Dr. Pharis Mohideen underscores the significance of the positive 3-year results from the EPITOPE Phase 3 extension study in this @GoHealio report, offering insights into our investigative #peanutallergy treatment and next steps for a #bla submission. Read more here: www.healio.com/news/allergy-asthma/20250121/patch-effecti…
-
DBV Technologies
@DBVTechnologies
This weekend, we’re heading to the Western Society of Allergy, Asthma & Immunology (WSAAI) 62nd Annual Scientific Session! We look forward to connecting with industry peers and showcasing the latest encouraging results from the VITESSE Phase 3 study for our investigational #peanutallergy treatment in children. Learn more about #wsaai and register here: wsaai.org
-
DBV Technologies
@DBVTechnologies
Allergic reactions to peanuts can vary. The same person might experience different reactions each time – ranging from mild symptoms like hives to more severe reactions affecting multiple body systems. For caregivers, understanding these differences is key to properly managing a child’s #peanutallergy. Learn more: acaai.org/allergies/allergic-conditions/food/
-
DBV Technologies
@DBVTechnologies
#foodallergies affect more than just the individual – they impact families, schools, workplaces, and entire communities. At DBV, we’re committed to advancing the potential of our VIASKIN® patch technology to meet the growing need for additional treatment options for food allergies. Learn more: dbv-technologies.com/our-science/
-
DBV Technologies
@DBVTechnologies
🤔 #dyk? Currently, there is no cure for food allergy – avoidance, education and preparedness remain essential for its management. Ongoing research is exploring ways to reduce allergen sensitivity, offering hope for new treatment options to help manage the condition. Stay informed and learn more about #foodallergies here: www.aaaai.org/tools-for-the-public/conditions-library/all…
-
DBV Technologies
@DBVTechnologies
We concluded 2024 and are entering 2025 with momentum for the VIASKIN® Peanut patch, our potential treatment option for toddlers aged 1–3 with #peanutallergy. With FDA alignment on an #acceleratedapproval Pathway and positive 3-year results from the EPITOPE Phase 3 OLE study, we’re excited to continue driving progress in our mission to transform #foodallergy care.
-
DBV Technologies
@DBVTechnologies
We’re at the Eastern Food Allergy & Comorbidity Conference in Palm Beach, FL! We look forward to showcasing encouraging new data from the EPITOPE Phase 3 OLE study. Find presentation details here: dbv-technologies.com/press_releases/dbv-technologies-anno… #efacc
-
DBV Technologies
@DBVTechnologies
We’re pleased to share positive results from the EPITOPE Phase 3 trial, including 3-year data from the Open-Label Extension (OLE) study of the VIASKIN® Peanut patch, our investigational peanut allergy treatment for toddlers aged 1-3. Highlights include increased treatment benefits and daily patch wear time data supporting our proposed labeling strategy. Join our webcast at 5:00 PM ET for more: dbv-technologies.com/press_releases/dbv-technologies-anno…
-
DBV Technologies
@DBVTechnologies
🌟 Happy Holidays from all of us at DBV! Wishing you and your loved ones a joyful, healthy, and peaceful holiday season.
-
DBV Technologies
@DBVTechnologies
This holiday season, we encourage you to be mindful of #foodallergies. When preparing meals, check ingredients, communicate with hosts, and plan ahead for a fun, festive, and worry-free holiday. Find more tips here: www.foodallergyawareness.org/holidays/preparing-for-holid…
-
DBV Technologies
@DBVTechnologies
At DBV, our mission is rooted in care and innovation. We’re exploring the potential of epicutaneous immunotherapy (EPIT) to advance treatment options for immunologic diseases that meet the needs of patients and their families. Learn more: dbv-technologies.com/about-dbv/
-
DBV Technologies
@DBVTechnologies
🤔 Myth or Fact? #foodallergies are not that serious.
Myth! Food allergies are a life-threatening, life-altering disease that can cause severe and potentially fatal allergic reactions. Find out more food allergy myths and facts from FARE @FoodAllergy here: -
DBV Technologies
@DBVTechnologies
We are pleased to announce that the FDA has formalized a regulatory pathway for the Accelerated Approval of our investigational product, the Viaskin® Peanut patch, in toddlers ages 1-3 with #peanutallergy. Join our conference call at 5pm ET to learn more: dbv-technologies.com/press_releases/dbv-confirms-alignmen…
-
DBV Technologies
@DBVTechnologies
We’re on a journey to potentially offer children and families affected by #foodallergies a novel treatment that aims to re-educate the immune system by introducing allergens through the skin. See how our technology platform works to learn more: dbv-technologies.com/our-science/viaskin-platform/
-
DBV Technologies
@DBVTechnologies
A comprehensive review of epicutaneous immunotherapy (EPIT) for the treatment of #peanutallergy was recently published in a peer-reviewed article by @AllergyEaaci. Discover how EPIT aims to re-educate the immune system through the skin: www.youtube.com/watch?v=iS9XjjM0EJs
-
DBV Technologies
@DBVTechnologies
Today, we express our gratitude for our dedicated team working tirelessly to advance solutions for #foodallergy patients. Our team's passion and commitment bring us closer to a safe and inclusive future for families affected by food allergies.
-
DBV Technologies
@DBVTechnologies
🍽️ For millions with #foodallergies, even small exposures can lead to life-threatening reactions. At DBV, we're focused on solutions to help families enjoy meals safely. Find Teal Thanksgiving tips here: www.foodallergy.org/resources/tips-and-takeaways-your-tea…
-
DBV Technologies
@DBVTechnologies
Join us in Athens, Greece as we sponsor @EAACI_HQ's FAAM-EUROBAT 2024! We will be hosting a symposium on Friday, November 22 and joining internationally acclaimed specialists to discuss the latest advancements in #foodallergy research and implications for diagnosis & treatment. We hope to see you there!
-
DBV Technologies
@DBVTechnologies
At DBV, patients are at the core of all we do. We're dedicated to advancing potential new treatment options to improve the lives of those affected by #foodallergies, a serious & life-changing condition that impacts millions. Learn more: dbv-technologies.com/our-science/viaskin-platform/
-
DBV Technologies
@DBVTechnologies
Great turnout at @FAACTNews’ Digital Influencer Summit! Our CMO, Pharis Mohideen, M.D., was invited to present on Innovation in the Allergy Community and advancements in the space, including the latest on our potential treatment option for children & toddlers with #peanutallergy.
-
DBV Technologies
@DBVTechnologies
We're proud to sponsor @FAACTNews' Digital Influencer Summit & tenth annual Global Food Industry and Research Summit. We look forward to connecting with peers to discuss safely meeting the needs of the #foodallergy community. Visit our booth to learn more: www.foodallergyawareness.org/events-and-programs/food-ind…
-
DBV Technologies
@DBVTechnologies
Today, we reported financial results for the third quarter of 2024. Read the full press release here: dbv-technologies.com/press_releases/dbv-technologies-repo…
-
DBV Technologies
@DBVTechnologies
We look forward to joining our #foodallergy peers at the @ACAAI Annual Scientific Meeting, where we will be hosting a product theater on Saturday, 10/26. Visit us at our booth to learn about our potential treatment for those with peanut allergy. More here: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
We’re pleased to announce positive regulatory updates for our investigational product, the Viaskin® Peanut Patch, including guidance on a pathway for Accelerated Approval for toddlers ages 1-3 with #peanutallergy. Join our conference call for more: dbv-technologies.com/press_releases/dbv-announces-positiv…
-
DBV Technologies
@DBVTechnologies
Our CMO, Pharis Mohideen, joined a FARE Neighborhoods Day panel to discuss using data & research to create more equitable futures for those with #foodallergies. We're grateful for the opportunity to participate in inspiring dialogue for a healthier, more inclusive future.
-
DBV Technologies
@DBVTechnologies
🔬 Our innovative technology platform, merges science & technology to change the way we think about #allergy treatment. It allows us to explore the potential of epicutaneous immunotherapy for children with #peanutallergy. Learn more here: dbv-technologies.com/our-science/viaskin-platform/
-
DBV Technologies
@DBVTechnologies
#icymi @KSTP explores the development of our investigational pediatric #peanutallergy treatment with Dr. Doug McMahon of the Asthma & Allergy Center of MN and our CMO, Dr. Pharis Mohideen, plus insights from a mother of a peanut-allergic child. To watch: kstp.com/kstp-news/top-news/clinical-trial-enrolling-chil…
-
DBV Technologies
@DBVTechnologies
Don't miss our lunch symposium at this year's World Allergy Congress. We will discuss our work to advance our lead candidate for the treatment of #peanutallergy. Learn more about the congress here: worldallergy.org/wao-meetings/wac-2024 @WorldAllergy
-
DBV Technologies
@DBVTechnologies
We are proud to share that we've completed screening for our VITESSE Phase 3 #clinicaltrial for children ages 4-7 with a #peanutallergy. We look forward to further advancing our clinical development program. Read more in our press release: dbv-technologies.com/press_releases/dbv-technologies-comp…
-
DBV Technologies
@DBVTechnologies
At DBV, we aim to develop safe & effective treatment options for #foodallergies. Driven by a passion for better health outcomes, we’re committed to advancing research & delivering solutions that address unmet need for patients & their families. Learn more: dbv-technologies.com/about-dbv/
-
DBV Technologies
@DBVTechnologies
🍎 As the school year kicks off, check out these #backtoschool snack tips from @AAAAIOrg to ensure a safe environment for children with #peanutallergy. Read more: www.aaaai.org/tools-for-the-public/conditions-library/all…
-
DBV Technologies
@DBVTechnologies
We’re proud to be a sponsor of the 2024 SEAAIS Annual Meeting and we look forward to attending this year’s conference alongside healthcare professionals in #allergy and #immunology. Be sure to check out our booth! Learn more here: seaai.org/conference/
-
DBV Technologies
@DBVTechnologies
Last week, DBV attended the ASCIA 2024 Conference, where we connected with peers and health professionals on the latest happenings in allergy and clinical immunology research. Learn more here: togelsdy2021.com @ascia_news
-
DBV Technologies
@DBVTechnologies
On September 9, our CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference. Sign up for the webcast here: journey.ct.events/view/deff6d72-d4d1-43f4-a965-915f00f1aec4 #hcwainwrightglobal
-
DBV Technologies
@DBVTechnologies
More children are living with #peanutallergy than ever before. In this @wjxt4 segment, #drdougmackmd discusses the increase in prevalence, and Sara Koreishi shares her experience as a mother of a peanut-allergic child. Watch here: www.news4jax.com/video/news/morning-show/2024/05/13/under…
-
DBV Technologies
@DBVTechnologies
🎒📚 #dyk about 8% of U.S. children (~2 in every classroom) have a #foodallergy, facing risk of a severe, potentially fatal allergic reaction? Let's make this school year safer for everyone! Check out some #peanutallergy tips for Back to School here: www.aaaai.org/tools-for-the-public/conditions-library/all…
-
DBV Technologies
@DBVTechnologies
#dyk that research suggests that fewer than 30% of people with a #peanutallergy are expected to outgrow it in their lifetime? At DBV, we're on a mission to develop a new class of epicutaneous immunotherapy to potentially treat #peanutallergy. Learn more: dbv-technologies.com/pipeline/
-
DBV Technologies
@DBVTechnologies
☀️🏊♀️ Poolside fun just got tastier! Dive into our #wordsearch and discover delicious #peanutallergy friendly snacks for summer days by the pool.
🔍 Can you find all the hidden treats? Share the words you find in the comments below!
*Remember to always check food labels* -
DBV Technologies
@DBVTechnologies
🔔 Attention #peanutallergy affected families! Our clinical study is exploring a potential new treatment option using a patch. Inquire about eligibility now: www.pujcovnasaticek.cz
-
DBV Technologies
@DBVTechnologies
The DBV team is attending the Tennessee Society of Allergy, Asthma, and Immunology 2024 August 9-11 in Pigeon Forge! Check out our booth to learn about our ongoing #clinicaltrial enrolling #peanutallergic children ages 4-7. More here: www.tsaai.org/
-
DBV Technologies
@DBVTechnologies
This weekend we attended @AAPAAAI 2024 in San Antonio, TX! Our booth had info about our #clinicaltrial currently enrolling children ages 4-7 with a #peanutallergy. It was great to connect with attendees & discuss how we can make a difference! More here: apaaai.wildapricot.org/Sys/Error/404 -
-
DBV Technologies
@DBVTechnologies
Today we provided a business update on our programs evaluating our investigational product in children (ages 4-7) and toddlers (ages 1-3) with #peanutallergy, and reported Q2 and 1H 2024 financial results. Read the full press release here: dbv-technologies.com/press_releases/dbv-technologies-prov…
-
DBV Technologies
@DBVTechnologies
Are you attending the Aspen Allergy Conference? We are presenting clinical data from the first year of our open-label extension study for our EPITOPE #clinicaltrial. Don't forget to check out our booth! Get the details here: aspenallergy.org
-
DBV Technologies
@DBVTechnologies
DBV is proud to sponsor @FL_AllergySoc's 2024 Annual Meeting in Orlando! Stop by our booth to learn more about our clinical trials involving #peanutallergy. Learn more here: www.faais.org/annual-meeting/ #faais2024
-
DBV Technologies
@DBVTechnologies
At this year's Global Food Allergy Prevention Summit, we shared a poster highlighting the open-label extension of our EPITOPE trial, as well as a poster on our Phase 3 VITESSE trial, both in #peanutallergy. More here: dbv-technologies.com/our-science/scientific-publications-…
-
DBV Technologies
@DBVTechnologies
Summer is here! Keep your 4th of July BBQ #foodallergy safe with these tips:
☀️ Label cups to avoid mix-ups
☀️ Label dishes with allergens
☀️ Thoroughly clean your grill, tables & other surfaces to remove traces of food
Read more here: www.foodallergy.org/resources/summer-bbq-tips-and-tricks -
DBV Technologies
@DBVTechnologies
DBV is a proud sponsor of the Global Food Allergy Prevention Summit in Chicago. We will present data from our open-label extension study in peanut-allergic toddlers & the study design for VITESSE in ages 4-7. Don't forget to visit our booth! Info here: preventfa.com
-
DBV Technologies
@DBVTechnologies
EPIT, a new class of non-invasive treatment under investigation, seeks to modify an individual's food allergy by re-educating the immune system to become desensitized to allergens. Discover our preclinical research here: dbv-technologies.com/our-science/viaskin-platform/
-
DBV Technologies
@DBVTechnologies
DBV is proud to be a sponsor at the Pennsylvania Allergy & Asthma Association (PAAA) 75th Annual Meeting. Visit our booth to learn about our Phase 3 #clinicaltrial in children with #peanutallergy. More info here: paaa.joynconference.com/v2/
-
DBV Technologies
@DBVTechnologies
Pediatric allergist @DrDougMackMD & Sarah Koreishi, mother of a peanut-allergic child, discussed the impact & prevalence of childhood peanut allergy, and our ongoing VITESSE clinical trial in peanut-allergic children 4-7 years old. Watch on @CW39Houston: www.youtube.com/watch?v=HlFhIv_nO0c
-
DBV Technologies
@DBVTechnologies
This week we're participating in @ACAAI's Corporate Council meeting. We look forward to collaborating with allergists, immunologists & industry peers to engage in joint problem-solving and explore opportunities to improve patient care for children living with #foodallergies.
-
DBV Technologies
@DBVTechnologies
DBV Technologies presented a poster at #eaacicongress2024 on data related to its lead product candidate for peanut allergy and accidental peanut consumption. Learn more: dbv-technologies.com/wp-content/uploads/2024/05/DBV242798…
-
DBV Technologies
@DBVTechnologies
Join DBV Technologies at the #eaacicongress2024 in Valencia, Spain. There are multiple opportunities to learn about our investigational product for treatment of #peanutallergy. Visit us at booth F10 to learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p… #eaaci @EAACI_HQ
-
DBV Technologies
@DBVTechnologies
DBV is sponsoring morning breaks on Friday and Saturday at the Eastern Allergy Conference. Visit us at our booth to learn more about our Phase 3 trial VITESSE in children with #peanutallergy. Learn more: easternallergyconference.org
-
DBV Technologies
@DBVTechnologies
#foodallergyawarenessweek is an opportunity to learn what it’s like to live with a #foodallergy. Our team wore teal to represent food allergy awareness and action, as part of #tealtakeover. Through innovation, we hope to make a better future for children with #peanutallergy.
-
DBV Technologies
@DBVTechnologies
We are proud to support advocacy organizations devoted to addressing the needs of people living with #foodallergies and similar conditions. Learn how you can lend your support too #foodallergyawarenessweek. @AllergyAsthmaHQ @FAACTnews @AAFANational @FoodAllergyCAN @FoodAllergy
-
DBV Technologies
@DBVTechnologies
We are committed to transforming the care of children with food allergy. During #foodallergyawarenessweek, this starts with understanding what it is like to live with a #foodallergy.
-
DBV Technologies
@DBVTechnologies
We attended #aadch2024 sponsored by the @AllergyAsthmaHQ on May 8 to help bring awareness to issues impacting individuals and families living with #foodallergies and related conditions. Learn more: allergyasthmanetwork.org/news/allergy-asthma-advocacy-aad…
-
DBV Technologies
@DBVTechnologies
Robert Pietrusko, PharmD, has joined our leadership team as Chief Regulatory Officer. Bob has more than four decades of biopharmaceutical regulatory experience leading to more than 35 drug approvals. We are thrilled to welcome him to our team. dbv-technologies.com/team/robert-pietrusko-pharmd/
-
DBV Technologies
@DBVTechnologies
Epicutaneous immunotherapy (EPIT™) with Viaskin™ introduces microgram amounts of a food allergen to the immune system through intact skin. Learn more about DBV's technology platform: dbv-technologies.com/our-science/viaskin-platform/
-
DBV Technologies
@DBVTechnologies
DBV Technologies Annual General Meeting of Shareholders will take place on May 16, 2024, at 10:00 a.m. CET at the Company’s offices in Châtillon, France. Learn more: dbv-technologies.com/events/2024-annual-general-meeting/
-
DBV Technologies
@DBVTechnologies
Stop by our booth at @TAAIS_tx Annual Meeting which starts today. To learn more about our work in advancing potential treatment for children living with #peanutallergy. Find out more: taais.org/2027meeting/
-
DBV Technologies
@DBVTechnologies
We moved! To support DBV’s growth and commitment to transforming the care of food allergic people, we moved our corporate headquarters to Châtillon, France and US operations to Warren, NJ. Find our new addresses here: dbv-technologies.com/contact-us/
-
DBV Technologies
@DBVTechnologies
DBV is sponsoring a faculty dinner and attendee lunch at the North American Pediatric Allergy & Asthma Congress. Visit us at booth 4 to learn about our Phase 3 trial VITESSE in children with #peanutallergy. Learn more: education.acaai.org/NAPAAC24
-
DBV Technologies
@DBVTechnologies
Watch a Medscape panel discussion on optimizing outcomes and emerging therapies in #peanutallergy sponsored by DBV at EFAC 2024. Intended for healthcare professionals who treat children with peanut allergy, it is now available for CME credit: login.medscape.com/login/sso/getlogin?sc=ng&dc=ma&wcode=1…
-
DBV Technologies
@DBVTechnologies
We look forward to attending this year's Allergy, Asthma, and Immunology Society of South Carolina Annual Meeting. Stop by our booth to learn more about epicutaneous immunotherapy for #peanutallergy. See full #aaissc conference details: scallergists.com/meetings/
-
DBV Technologies
@DBVTechnologies
Clinical data of our investigational Viaskin ™ Peanut from ~1000 children aged 1-11 with #peanutallergy were recently published in a review article in Expert Review of Clinical Immunology. Read more here:
www.tandfonline.com/doi/full/10.1080/1744666X.2024.2315221 -
DBV Technologies
@DBVTechnologies
Today we provided a business update on Viaskin™ Peanut, our investigational product for children with #peanutallergy, and reported full year 2023 financial results. Read the full press release here: dbv-technologies.com/press_releases/dbv-technologies-repo…
-
DBV Technologies
@DBVTechnologies
5-year safety results of Viaskin™ Peanut, our investigational #peanutallergy treatment for children, was featured in @ContemporaryPEDS in an interview with allergist, Dr. David M. Fleischer. Found here: www.contemporarypediatrics.com/view/long-term-safetyepicu…
-
DBV Technologies
@DBVTechnologies
On Thursday, March 7th, we will report full year 2023 financial results and provide a business update. Tune in to the live conference call webcast at 5 p.m. ET: dbv-technologies.com/press_releases/dbv-technologies-to-r…
-
DBV Technologies
@DBVTechnologies
Today at #aaaai24 we presented long-term safety data from our PEOPLE open-label extension study of Viaskin™ Peanut in children. Learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
At #aaaai24 DBV presents 5-year safety data from long-term study of children with #peanutallergy treated with Viaskin™ Peanut; and BAT, a potential biomarker DBV is studying as a possible predictor of oral food challenge outcomes. Read more: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
We’re sponsoring a Product Theater at #aaaai24 where Hugh Sampson, Julie Wang, & David Fleischer will discuss navigating the decision-making process after a #peanutallergy diagnosis, from early treatment initiation to clinical trial participation, & more: aaaai.planion.com/Web.User/SesDet?ACCOUNT=AAAAI&CONF=AM20…
-
DBV Technologies
@DBVTechnologies
Join DBV Technologies at #aaaai24 February 23-26 in Washington D.C. There are multiple opportunities to learn about Viaskin™ Peanut, our investigational product for treatment of #peanutallergy. Visit us at Booth #567 and learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
At #aaaai24 February 23-26 in Washington D.C., we will be presenting data and discussing our ongoing efforts to further the development of Viaskin™ Peanut as a potential treatment option for children with #peanutallergy. Learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
Viaskinᵀᴹ, our investigational #peanutallergy treatment for toddlers & children, was featured in @ContempPEDS in an interview with pediatric allergist, Dr. Matthew Greenhawt. Found here: www.contemporarypediatrics.com/view/a-discussion-of-epicu…
-
DBV Technologies
@DBVTechnologies
After two years with Viaskinᵀᴹ Peanut, 81% of toddlers with #peanutallergy achieved an increase in eliciting dose (amount of peanut that causes an allergic reaction) from less than 1 peanut to 3-4 peanuts in our long-term extension trial. Learn more: dbv-technologies.com/wp-content/uploads/2023/11/Greenhawt…
-
DBV Technologies
@DBVTechnologies
We are pleased to welcome Kevin P. Malobisky, Ph.D., M.S., RAC, as a Chief Operations Officer here at DBV. Learn more about Kevin and our experienced leadership team: dbv-technologies.com/about-dbv/leadership/
-
DBV Technologies
@DBVTechnologies
ICYMI, after two years of Viaskinᵀᴹ Peanut treatment, 56% of toddlers with #peanutallergy ate an equivalent of 12-14 peanuts without experiencing an allergic reaction during the year-two food challenge in our long-term extension trial. Learn more: dbv-technologies.com/wp-content/uploads/2023/11/Greenhawt…
-
DBV Technologies
@DBVTechnologies
ICYMI, a second year of Viaskinᵀᴹ Peanut resulted in continued or improved treatment benefit for most toddlers aged 1-3 with #peanutallergy. Our long-term extension study interim data shows 4/5 participants were treatment responders at year-two. Read: dbv-technologies.com/wp-content/uploads/2023/11/Greenhawt…
-
DBV Technologies
@DBVTechnologies
Our EPITOPE trial of Viaskinᵀᴹ Peanut in toddlers with #peanutallergy, published in @NEJM, is now available in easy-to-understand language in @fsgimt. Find out more about the results from the editorial called “Good News for Toddlers with Peanut Allergy”: www.tandfonline.com/doi/10.2217/imt-2023-0201
-
DBV Technologies
@DBVTechnologies
2023 was a tremendous year as we made strides for those living with #peanutallergy with positive Phase 3 results published in @NEJM. In 2024 we continue our unwavering commitment to advancing treatment options for peanut and other food allergies.
dbv-technologies.com -
DBV Technologies
@DBVTechnologies
Happy Holidays from DBV Technologies.
-
DBV Technologies
@DBVTechnologies
We are pleased to share that we have published an in-depth review paper on the science behind epicutaneous immunotherapy (EPIT) in @FrontiersIn Allergy, along with senior author Hugh Sampson, MD. Read the open-access article to learn about our technology. www.frontiersin.org/journals/allergy/articles/10.3389/fal…
-
DBV Technologies
@DBVTechnologies
#icymi, DBV attended this year’s ACAAI Annual Scientific Meeting last week. To learn more about our activities at the meeting, including a late-breaking abstract, visit our website: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
Test your knowledge across allergy and immunology at the 32nd Annual FIT Bowl taking place tonight, Saturday, 11/11, from 5:45 to 7:45 PST! DBV is proud to sponsor the most anticipated event at #acaai23. college.acaai.org/fits-join-the-2023-fit-bowl-competition/
-
DBV Technologies
@DBVTechnologies
We are looking forward to this year’s @ACAAI Annual Scientific Meeting! Our Product Theater session will focus on individualizing peanut allergy management through case-based learning. Learn more: annualmeeting.acaai.org
-
DBV Technologies
@DBVTechnologies
Stop by our booth (#319) at the #acaai23 exhibit hall to view more about our lead product candidate designed to reduce the risk of allergic reactions due to accidental exposure to peanuts.
-
DBV Technologies
@DBVTechnologies
We are excited to be at the @ACAAI Annual Scientific Meeting (#acaai23) to present data and engage with peers on the evolution of patient care in the allergy space. Stop by our booth (#319) and make sure to catch our late-breaking abstract presentation on Saturday at 9:35 am PT.
-
DBV Technologies
@DBVTechnologies
We are proud to announce interim results from our ongoing Phase 3 Open-Label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in Toddlers. Visit here to read our press release and learn more: dbv-technologies.com/press_releases/dbv-technologies-anno…
-
DBV Technologies
@DBVTechnologies
We are pleased to announce that we will present data on our investigational Viaskin Peanut in toddlers at the @ACAAI Annual Scientific Meeting. Read the release to learn more: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
Today, we announced that DBV received requested FDA feedback on protocol design elements for the COMFORT Toddlers and COMFORT Children supplemental safety studies. We also issued financial results for the third quarter of 2023. Read the full press release: dbv-technologies.com/press_releases/dbv-technologies-rece…
-
DBV Technologies
@DBVTechnologies
Halloween should be fun for all kids and their families! The #tealpumpkinproject aims to make trick-or-treating safer for families living with #foodallergies. Place a teal pumpkin on your doorstep and check out these ideas for non-food treats: community.aafa.org/blog/keep-kids-with-allergies-and-asth…
-
DBV Technologies
@DBVTechnologies
DBV will have a presence at the @CSACI_ca Annual Scientific from October 19-22 in Ottawa, Ontario. Visit our booth to read our poster contributing to the knowledge on the natural history of peanut allergy: am.csaci.ca
-
DBV Technologies
@DBVTechnologies
We’re pleased to announce the appointment of Virginie Boucinha as our Chief Financial Officer, effective November 6. Learn more: dbv-technologies.com/press_releases/dbv-technologies-anno…
-
DBV Technologies
@DBVTechnologies
Today marks the beginning of this year's @FARE Food Allergy Summit in Orlando. Our VP of Clinical Development and Medical Affairs, Todd Green, will discuss innovations in the food allergy community at the Innovation Panel Fireside Chat. Read more: www.foodallergy.org/take-action/food-allergy-summit
-
DBV Technologies
@DBVTechnologies
DBV will be attending the Northwest Allergy Forum hosted by the Oregon Society of Allergy, Asthma, & Immunology (OSAAI) and the Greater Washington Allergy, Asthma, & Immunology Society (GWAAIS) Oct 13-15 in Portland, Oregon. Be sure to visit!
-
DBV Technologies
@DBVTechnologies
In this @PharmaVoice article, our CMO, Pharis Mohideen, shares his personal connection to our mission to develop treatments for patients with #foodallergies: www.pharmavoice.com/news/dbv-technologies-peanut-allergy-…. Viaskin technology is under clinical investigation & is not yet approved by regulatory authority.
-
DBV Technologies
@DBVTechnologies
We will be holding an exhibit booth on DBV's dedication to improving the lives of patients with #foodallergies. Find out more about #seais: seaai.org/conference/
-
DBV Technologies
@DBVTechnologies
We are deeply committed to advancing treatment for patients with #foodallergies and their families. Our research in #immunotherapy aims to re-educate patients' immune systems by introducing allergens through the skin: dbv-technologies.com/about-dbv/
-
DBV Technologies
@DBVTechnologies
DBV is excited to join other industry leaders at the @FAACTnews Food Industry Research Summit in Illinois September 10 – 12. Conversations will center around food allergies in the United States. Learn about FAACT and their mission here: www.foodallergyawareness.org
-
DBV Technologies
@DBVTechnologies
Our EPITOPE Phase 3 trial, evaluating our investigational Viaskin Peanut, found epicutaneous immunotherapy superior to placebo in desensitizing to peanuts & increasing the peanut dose required to trigger allergy symptoms. Read the trial findings in @NEJM: www.nejm.org/stoken/default+domain/REPRINTS_35783A/full?r…
-
DBV Technologies
@DBVTechnologies
A true #milkallergy involves the immune system whereas a milk protein intolerance or lactose intolerance does not, and each condition is treated differently. Read more about milk allergy causes and symptoms: acaai.org/allergies/allergic-conditions/food/milk-dairy/
-
DBV Technologies
@DBVTechnologies
When the body misidentifies #peanutproteins as something harmful, #peanutallergy symptoms can occur in multiple areas such as the skin, lungs and throat. Learn about signs and symptoms: acaai.org/news/peanut-patch-treatment-continues-to-help-t…
-
DBV Technologies
@DBVTechnologies
Today, we announced that DBV received FDA feedback on study design elements for the Viaskin Peanut safety studies. We also issued financial results for the second quarter and first half of 2023. Read the full press release here: dbv-technologies.com/press_releases/dbv-technologies-rece…
-
DBV Technologies
@DBVTechnologies
From July 30-August 3, the DBV team will be attending the Aspen Allergy Conference and hosting an exhibit booth. Visit our booth during the conference and read more about our work here: dbv-technologies.com/about-dbv/
-
DBV Technologies
@DBVTechnologies
On Monday, July 31st, we will be reporting our first half 2023 financial results and providing a corporate update. Tune in for the conference call and live audio webcast at 5:00 p.m. ET: dbv-technologies.com/press_releases/dbv-technologies-to-r…
-
DBV Technologies
@DBVTechnologies
We prioritize patients in everything we do and our science aims to improve the lives of those living with #foodallergies and other #immunological diseases. Learn about our investigative efforts: dbv-technologies.com/our-science/
-
DBV Technologies
@DBVTechnologies
This week, our team will be attending the Florida Allergy, Asthma and Immunology Society Meeting. We will be holding an exhibit booth on DBV's dedication to improving the lives of patients with #foodallergies. Find out more about #faais23: www.faais.org/annual-meeting/ @FL_AllergySoc
-
DBV Technologies
@DBVTechnologies
At the Global Food #allergy Prevention Summit, we will have a poster by Dr. Aikaterini Anagnostou on additional clinical data analyses & DBV’s Dr. Todd Green will be a part of a panel update on our investigational treatment at 5pm CT on July 8: www.feinberg.northwestern.edu/sites/cfaar/GFAPS-2023/inde… #gfaps2023
-
DBV Technologies
@DBVTechnologies
During the Pennsylvania #allergy & #asthma Association Annual Meeting, DBV will be hosting a booth & sponsoring an educational research event for fellows in the fields of allergy and immunology. See full #paaa conference details: www.paallergy.org/annual-meeting.html
-
DBV Technologies
@DBVTechnologies
At DBV, our mission to progress epicutaneous #immunotherapy drives our commitment to the advancement of treatments for patients and their families. Read more about the science here: dbv-technologies.com/our-science/
-
DBV Technologies
@DBVTechnologies
On June 14, our CEO Daniel Tassé will be hosting a fireside chat webcast and scheduling 1X1 meetings at this year's @GoldmanSachs 44th Annual #globalhealthcare Conference. Sign up for the webcast: event.webcasts.com/starthere.jsp?ei=1617085&tp_key=56e387…
-
DBV Technologies
@DBVTechnologies
On June 10 during #eaaci2023, we will be hosting a symposium with Dr. Stefania Arasi, Dr. Susanne Lau, Dr. Sabine Schnadt and Dr. George Du Toit on 'Addressing the burden of patients living with #peanutallergy.' Learn more about the symposium here: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
From June 9-11, our team will be presenting three posters at the European Academy of Allergy & Clinical Immunology Congress (@EAACI_HQ), including data from our Phase 3 EPITOPE study. Learn more about our involvement in #eaaci2023: dbv-technologies.com/press_releases/dbv-technologies-to-p…
-
DBV Technologies
@DBVTechnologies
Today at the Eastern Allergy Conference (#eac2023), our team will have three posters around our VITESSE & EPITOPE #peanutallergy studies, one of which will feature new data. Learn more here: easternallergyconference.org/2023-abstracts-%2F-posters
-
DBV Technologies
@DBVTechnologies
Managing a child's #foodallergies can be stressful. @FoodAllergy provides resources to help navigate your child's day-to-day. Learn more: www.foodallergy.org/living-food-allergy/information-you/c… #faam
-
DBV Technologies
@DBVTechnologies
Tomorrow during the @worldallergy Symposium, Dr. David Fleischer will be presenting an oral abstract on our VITESSE study in #peanutallergic children aged 4-7 years. Learn more about our study here: clinicaltrials.gov/ct2/show/NCT05741476
-
DBV Technologies
@DBVTechnologies
According to @AAFAnational, there are three basic principles to managing #foodallergies: seeing an #allergist to confirm your allergy, taking steps to prevent allergic reactions, and being prepared to treat a severe reaction. Learn more here: aafa.org/allergies/types-of-allergies/food-allergies/
@kfatweets -
DBV Technologies
@DBVTechnologies
During #faaw, we emphasize our commitment to supporting the food allergy community & raising awareness. We thank our partner patient groups for their resources & continued collaboration! @AllergyAsthmaHQ @FAACTnews @AAFANational @FoodAllergy @kfatweets
#tealtakeover -
DBV Technologies
@DBVTechnologies
#icymi, @NEJM recently published our Phase 3 EPITOPE trial evaluating our investigational Viaskin Peanut in toddlers. Read the full publication: www.nejm.org/doi/full/10.1056/NEJMoa2212895
-
DBV Technologies
@DBVTechnologies
We are excited to have our EPITOPE Phase 3 trial evaluating our investigational Viaskin Peanut in children 1-3 years published in The New England Journal of Medicine (@NEJM ). Watch below and read the publication here: www.nejm.org/doi/full/10.1056/NEJMoa2212895
-
DBV Technologies
@DBVTechnologies
We're proud to share that @NEJM has published our EPITOPE Phase 3 trial evaluating our investigational Viaskin Peanut in #peanutallergic children 1-3 years. Learn more here: dbv-technologies.com/press_releases/dbv-technologies-anno…
-
DBV Technologies
@DBVTechnologies
We’re proud to have joined @AllergyAsthmaHQ’s advocacy and awareness efforts for those with #asthma and #allergies on Capitol Hill yesterday! #foodallergyawarenessmonth #faam
Allergy & Asthma Network
@AllergyAsthmaHQ
Today is the BIG day, Asthma & Allergy Day on Capitol Hill! Let's raise awareness and advocate for better care and support for those with asthma and allergies. Together, we can make a difference and help create a safer and healthier environment for everyone.
#aadch2023 #asthma -
DBV Technologies
@DBVTechnologies
#dyk that around 6 million children in the U.S. are living with a #foodallergy? DBV is committed to raising awareness for this important community every day and especially during #foodallergyawarenessmonth. Get involved here: www.foodallergyawareness.org/education/food-allergy-aware… #faam @FAACTnews
-
DBV Technologies
@DBVTechnologies
Our innovative platform, Viaskin, seeks to transform #foodallergy treatment by delivering microgram amounts of allergens to the #immunesystem through skin contact. Learn more about our technology here: www.dbv-technologies.com/our-science/
-
DBV Technologies
@DBVTechnologies
In this HCPLive (@MDMagazine) interview segment, David Fleischer, M.D., discusses our investigational immunotherapy treatment in #peanutallergic children, and our VITESSE Phase 3 clinical trial. Learn more here: www.hcplive.com/view/david-fleischer-md-benefits-immunoth…
-
DBV Technologies
@DBVTechnologies
We are pleased to announce FDA provided pre-BLA written response on regulatory path for Viaskin Peanut patch in 1-3 year olds with confirmed peanut allergy. Read more here: dbv-technologies.com/press_releases/dbv-technologies-outl…
-
DBV Technologies
@DBVTechnologies
Our company was founded by pediatricians with the mission to improve the lives of children with #foodallergies through epicutaneous immunotherapy. Learn more about us and our mission here: www.dbv-technologies.com/about-dbv/
-
DBV Technologies
@DBVTechnologies
Happy #worldhealthday! We’re proud to support @WHO and their mission to promote #healthforall. Our team is committed to improving the lives of patients with #foodallergies and that starts with spreading awareness.
-
DBV Technologies
@DBVTechnologies
We are excited to announce the first patient screened in our VITESSE Phase 3 clinical trial in #peanutallergic children 4-7 years old. Read more about our trial here: www.globenewswire.com/news-release/2023/03/07/2622588/0/e…
-
DBV Technologies
@DBVTechnologies
Today, we announced financial results for the fourth quarter of 2022 and other key business updates. Read the full press release here: ml-eu.globenewswire.com/Resource/Download/0b3afd6e-cb5c-4…
-
DBV Technologies
@DBVTechnologies
Our DBV team is excited to be attending this year's #aaaai23 Annual Meeting . Visit us at booth 1826 to meet members of our team and to learn more about our investigational technology platform: www.dbv-technologies.com/wp-content/uploads/2023/02/press…
-
DBV Technologies
@DBVTechnologies
Dr. David Fleischer and Dr. Amy Scurlock will present on #immunotherapy for #peanutallergies in relation to our EPITOPE study on February 24 at #aaaai23. Learn more about our poster presentations here: www.dbv-technologies.com/wp-content/uploads/2023/02/press… @AAAAI_org
-
DBV Technologies
@DBVTechnologies
During #aaaai23, we will be featuring a non-CME Product Theater with two KOLs on the Immunological Role of the Skin in Food allergy. Learn more about the event on February 25th: annualmeeting.aaaai.org @AAAAI_org
-
DBV Technologies
@DBVTechnologies
We will be participating in the upcoming 2023 @AAAAI_org Annual Meeting from February 24-27 in San Antonio, TX, presenting data from our Phase 3 EPITOPE study. Read more here: www.globenewswire.com/news-release/2023/02/21/2612739/0/e… #aaaai23
-
DBV Technologies
@DBVTechnologies
We’re here at #acaai22 for one more day! Stop by our booth (#804) tomorrow to hear how we’re working to transform care for patients with #foodallergy and other immunological diseases. Learn more about our science: www.dbv-technologies.com/our-science/
-
DBV Technologies
@DBVTechnologies
Today at #acaai22, Dr. Matthew Greenhawt will present topline results from the EPITOPE study in toddlers with #peanutallergy (ID: D019). Join him at 4:30 pm to learn more, and then head over to the 31st Annual FIT Bowl competition at 5:30, which we’re proud to sponsor.
-
DBV Technologies
@DBVTechnologies
Our #acaai22 booth opens at 2 pm today – stop by #804 to say hello! And don’t miss Dr. Terri Brown-Whitehorn’s e-Poster presentation at 3 in the Exhibit Hall (Monitor 16) on changes in reaction severity during the EPITOPE trial (ID: P183).
-
DBV Technologies
@DBVTechnologies
We’re kicking things off at #acaai22 today as the sole sponsor of the International Food Allergy Symposium. Join us to hear from global experts on everything from epidemiology and prevention to diagnostics and treatment. annualmeeting.acaai.org/2022/intl_food_allery_symposium.cfm
-
DBV Technologies
@DBVTechnologies
See our latest @JACIInPractice publication featured by @AAAAI_org highlighting results of DBV's randomized, double-blind, placebo-controlled Phase 3 clinical trial, REALISE, assessing safety of Viaskin Peanut in peanut-allergic children aged 4-11 years. www.aaaai.org/tools-for-the-public/latest-research-summar…
-
DBV Technologies
@DBVTechnologies
We’re proud to report positive topline results from the Phase 3 EPITOPE trial of Viaskin Peanut in peanut-allergic toddlers. Learn more: www.dbv-technologies.com/wp-content/uploads/2022/06/epito…
-
DBV Technologies
@DBVTechnologies
DBV colleagues had so much fun supporting #aadch 2022 with @AAN in Washington, DC. We appreciated being able to support the patient community!
Allergy & Asthma Network
@AllergyAsthmaHQ
Thank you to everyone who participated in this year’s #aadch! Your efforts in advocating for asthma, allergies, and related conditions does not go unnoticed and does have a lasting impact. Stay tuned for more on #aadch2022, coming soon!
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
Food Allergy Awareness Week isn't over yet. There is still time to rock your teal! #tealtakover
-
DBV Technologies reposted
AAFA National
@AAFANational
32 million people in the United States live with #foodallergies, including almost 6 million children. While there are many food allergies, there are some that are more common.
Learn more about food allergies during #foodallergyawarenessweek this week. www.kidswithfoodallergies.org/food-allergy-facts.aspx -
DBV Technologies
@DBVTechnologies
We’re excited to kick off Food Allergy Awareness Week. At DBV, families impacted by food allergies are at the core of everything we do. #faaw #tealtakeover
-
DBV Technologies
@DBVTechnologies
Wishing “bonne chance”, or good luck to contestants of the 30th annual #acaai21 FIT Bowl, which we’re proud to sponsor
-
DBV Technologies
@DBVTechnologies
Today at #acaai21, Dr. Terri Brown-Whitehorn will present 3-year results from the REALISE study (Session D030). Learn more about our science: www.dbv-technologies.com/our-science
-
DBV Technologies
@DBVTechnologies
We're at the #acaai21 meeting. Be sure to check out our booth (#329) to learn about our dedication to improving the lives of patients with #foodallergy and other immunological diseases
-
DBV Technologies
@DBVTechnologies
Thanks to everyone who shared their story earlier this month at the first-ever Food Allergy Patient Focused Drug Development meeting. If you didn’t get a chance to attend, you still have until October 9th to share your story with the #fda. Learn more: foodallergycollaborative.org/pfdd-live/
-
DBV Technologies
@DBVTechnologies
What are the biggest challenges you face managing #foodallergies? Tomorrow, the first-ever Food Allergy Patient Focused Drug Development meeting invites you to share your experience with the #fda. To attend, please visit: foodallergycollaborative.org/register-for-the-patient-foc…
-
DBV Technologies reposted
KidsWithFoodAllergies
@kfatweets
Some food allergies are more likely to be outgrown than others: milk, egg, wheat and soy. www.kidswithfoodallergies.org/newly-diagnosed.aspx #foodallergyfacts #foodallergyawareness
-
DBV Technologies
@DBVTechnologies
Join us in supporting the millions of Americans living with food allergies by wearing teal today. #tealtakeover #faaw
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
We are thrilled to share that the @EmpireStateBldg will shine in teal TOMORROW NIGHT, as part of #foodallergyawarenessweek! From sunset until 2AM the next day, this iconic landmark will bring attention to a disease that affects 85 million Americans.
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
It's finally here....#foodallergyawarenessweek and we are so excited! Join us all week as we celebrate this strong community with recipes, quiz shows, innovations in science, advocacy, and more! You aren't going to want to miss a minute. www.foodallergy.org/our-initiatives/awareness-campaigns/f…
-
DBV Technologies reposted
KidsWithFoodAllergies
@kfatweets
Happy Mother's Day from Kids With Food Allergies! Every year, Food Allergy Awareness Week begins on Mother's Day. Your kids may not be old enough to tell you this yet, so we will. Thank you for everything you do to keep your child with food allergies safe, healthy and included.
-
DBV Technologies
@DBVTechnologies
We’re excited to kick off Food Allergy Awareness Week. At DBV, families impacted by food allergies are at the core of everything we do. #faaw
-
DBV Technologies
@DBVTechnologies
May is Food Allergy Awareness Month! Join us in raising awareness for the millions of families impacted by food allergies. #faam
-
DBV Technologies
@DBVTechnologies
We’re excited to join our #allergyimmunology community at the virtual #aaaai21 meeting where we’ll be presenting new data on #epit – if you’re attending, be sure to check out our virtual booth (Deluxe Hall A-H) and the FIT Networking Lounge Sponsored by DBV Technologies!
-
DBV Technologies
@DBVTechnologies
The Journal of Allergy and Clinical Immunology has published results from our three-year, open-label extension of the Phase III PEPITES study (PEOPLE). Read more here: www.dbv-technologies.com/wp-content/uploads/2020/07/dbv_j…
-
DBV Technologies
@DBVTechnologies
Presentations at this year’s digital #eaaci2020 highlight the breadth of research DBV is conducting on the science and impact of #foodallergy: www.dbv-technologies.com/pipeline/scientific-publications…
-
DBV Technologies
@DBVTechnologies
Two of our #eaaci2020 late-breaker presentations (abstracts 1739 and 1776) highlight pathways for biomarker identification in #foodallergy: www.dbv-technologies.com/pipeline/scientific-publications…
-
DBV Technologies
@DBVTechnologies
Virtually attending #eaaci2020? Don’t miss Dr. Philippe Begin present data from our pivotal Phase III investigational epicutaneous immunotherapy for #peanutallergy trial in children with and without multiple #foodallergies scientific.eaaci.org/site/programme/?a=eaaci2020dc
-
DBV Technologies
@DBVTechnologies
We’re proud to present data at this year’s digital #eaaci2020 highlighting investigational epicutaneous immunotherapy across patient populations plus biomarker identification data www.dbv-technologies.com/wp-content/uploads/2020/06/dbv-t…
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
From the dedication of our community to working with our champions on Capitol Hill, we are so proud of the work we have done and the progress we've made TOGETHER to bring forth positive changes in the name of #foodallergy! #faaw #advocacy www.foodallergy.org/our-initiatives/advocacy/food-allergy…
-
DBV Technologies reposted
Allergy & Asthma Network
@AllergyAsthmaHQ
We hear a lot about peanut and tree nut allergies. So let’s talk about milk – “the overlooked food allergen.” It affects about 2.5% of children younger than 3. Milk can be one of the most difficult allergens to avoid. #foodallergyawarenessweek
allergyasthmanetwork.org/milk-the-overlooked-food-allergen/ -
DBV Technologies reposted
Allergy & Asthma Network
@AllergyAsthmaHQ
For many, food allergy awareness starts with making dietary decisions based on food labels. Understanding the requirements that govern food allergy labeling can make those decisions easier. allergyasthmanetwork.org/11479 #foodallergyawarenessweek
-
DBV Technologies
@DBVTechnologies
#covid19 is significantly impacting all our lives, including families and loved ones with food allergies who are dealing with unique stress and challenges. It’s #foodallergyawarenessweek and we’re committed more than ever to making a difference. dbv-technologies.com #faaw
-
DBV Technologies
@DBVTechnologies
Join us at #aaaai20 March 13-16 where we’ll present detailed safety and efficacy data of Viaskin Peanut: www.dbv-technologies.com/wp-content/uploads/2020/02/dbv-t…
-
DBV Technologies
@DBVTechnologies
What exactly happens when your skin encounters an allergen?
DBV Technologies
@DBVTechnologies
Special cells in the skin called Langerhans cells are like the body’s security guards – they capture and bring allergens to the immune system to determine whether or not they’re safe.
DBV Technologies
@DBVTechnologies
Want to learn more about the work DBV is doing in food allergies? Visit www.dbv-technologies.com/viaskin-platform/
-
DBV Technologies
@DBVTechnologies
We’re pleased to report positive three-year, long-term data from the PEOPLE Phase III open-label extension study of Viaskin Peanut in children with peanut allergy. Learn more: www.dbv-technologies.com/wp-content/uploads/2020/01/dbv-t…
-
DBV Technologies
@DBVTechnologies
#dyk that fear of life-threatening reactions triggered by accidental peanut exposure can lead to increased anxiety? We are committed to improving the lives of #peanutallergy patients and their families. Learn more at dbv-technologies.com
-
DBV Technologies
@DBVTechnologies
For more than 15 years, we’ve been striving to develop treatments for patients suffering with the burden and life-threatening risk of #foodallergy Learn more at dbv-technologies.com
-
DBV Technologies
@DBVTechnologies
What happens when your skin encounters an allergen?
Post not available here, view on X
DBV Technologies
@DBVTechnologies
But if your body can learn the allergen isn’t a threat, special T cells called regulatory T cells may tell your immune system to stand down.
DBV Technologies
@DBVTechnologies
Want to learn more about how this relates to the work DBV is doing? Visit www.dbv-technologies.com/viaskin-platform/
-
DBV Technologies
@DBVTechnologies
Thank you to @ACAAI for another excellent meeting – we’re thrilled to have attended #acaai19. Read more about our three oral presentations and ePoster session here: www.dbv-technologies.com/wp-content/uploads/2019/10/dbv-t…
-
DBV Technologies
@DBVTechnologies
Dr. Matthew Greenhawt will present research on perceptions among children with #peanutallergy from 4:55-5:05 p.m. today in the George R. Brown Convention Center, Room 370. #acaai19
-
DBV Technologies
@DBVTechnologies
At #acaai19? Visit the Distinguished Industry Oral Abstracts session today from 5:05-5:15 p.m. in the George R. Brown Convention Center, Room 370.
-
DBV Technologies
@DBVTechnologies
Join @DunnGalvin for her presentation on quality of life from 5:15-5:25 p.m. today in the George R. Brown Convention Center, Room 370. #acaai19
-
DBV Technologies
@DBVTechnologies
Attending #acaai19? Be sure to stop by booth #507 to learn about our dedication to improving the lives of patients with #peanutallergy
-
DBV Technologies
@DBVTechnologies
Don’t miss @MarcusShaker present on the economic burden associated with #peanutallergy tomorrow from 11:30-11:45 a.m. in the George R. Brown Convention Center, Halls A3 & B3, Monitor 7. #acaai19
-
DBV Technologies
@DBVTechnologies
#acaai19 abstracts, including our three oral presentations and ePoster session, are now available online. Learn more at: www.dbv-technologies.com/wp-content/uploads/2019/10/dbv-t…
-
DBV Technologies
@DBVTechnologies
#peanutallergy places a significant burden on children and families, often due to uncertainty around accidental exposure. Be sure to stop by the International Food Allergy Symposium at #acaai19 to learn more about #foodallergy prevention and treatment.
-
DBV Technologies reposted
Allergy & Asthma Network
@AllergyAsthmaHQ
Stay safe this #halloween.
If you have asthma, dress warmly if it's chilly out and keep away from fog machines.
If you have food allergies, remember to avoid candies that contain your allergens (peanut, tree nuts, dairy, egg, etc.) And always check candy product labels!
Allergy & Asthma Network
@AllergyAsthmaHQ
Your child is no doubt eager to scare up a memorable Halloween costume and go trick-or-treating. Unfortunately, Halloween can be hazardous for kids who are at risk for an asthma flare-up or a food-allergic reaction to candy. www.allergyasthmanetwork.org/allergy-safe-halloween-happy…
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
#halloween can be disappointing for children and stressful for parents when #foodallergies are involved. We’re so glad to see the #tealpumpkinproject catching on across the country, making the holiday more fun for everyone! www.chicagotribune.com/business/ct-biz-halloween-candy-al…
-
DBV Technologies
@DBVTechnologies
Join us at #acaai19 Nov. 7-11 where we’ll present our research on the significant burden of peanut allergy: www.dbv-technologies.com/wp-content/uploads/2019/10/dbv-t…
-
DBV Technologies
@DBVTechnologies
Read more about the FDA acceptance of our BLA filing for Viaskin Peanut, an investigational epicutaneous immunotherapy patch: www.dbv-technologies.com/wp-content/uploads/2019/10/dbv-t…
-
DBV Technologies
@DBVTechnologies
We’re pleased to announce that the U.S. FDA accepted our BLA filing for Viaskin Peanut. Learn more: www.dbv-technologies.com/wp-content/uploads/2019/10/dbv-t…
-
DBV Technologies
@DBVTechnologies
Thank you, @EAACI_HQ, for the opportunity to present at this year’s congress. We are proud to be part of the #foodallergies and #peanutallergy community. You can access our posters through DBV’s press release here: www.dbv-technologies.com/wp-content/uploads/2019/06/dbv-t…
-
DBV Technologies
@DBVTechnologies
Attending #eaaci2019? Make sure to catch the Satellite Symposium titled: What are the clinical trial insights in peanut allergy with investigational EPIT? #foodallergies #peanutallergy
-
DBV Technologies
@DBVTechnologies
Don’t miss @AmyScurlock present at #eaaci2019 on investigational epicutaneous immunotherapy (#epit) for #peanutallergy at 14:47 in Hall 13 www.dbv-technologies.com/wp-content/uploads/2019/06/dbv-t…
-
DBV Technologies
@DBVTechnologies
Join us to discover more about investigational epicutaneous immunotherapy (#epit) in cashew allergy at #eaaci2019 between 12:15-13:45 poster TP1250 #foodallergies www.dbv-technologies.com/wp-content/uploads/2019/06/dbv-t…
-
DBV Technologies
@DBVTechnologies
Learn more about a post-hoc analysis study on investigational epicutaneous immunotherapy (#epit) for children w/ asthma and #peanutallergy from 10:30-13:00 in #eaaci2019 e-Poster Area D (poster LB PDS 1719) #foodallergies www.dbv-technologies.com/wp-content/uploads/2019/06/dbv-t…
-
DBV Technologies
@DBVTechnologies
Welcome to #eaaci2019! Come say “hello” and check out our booth to learn more about our work in #foodallergies and #peanutallergy (Booth #c02)
-
DBV Technologies
@DBVTechnologies
Join us at #eaaci2019 where we’ll present clinical trial data on the use of investigational epicutaneous immunotherapy (#epit) treatment in #foodallergies #peanutallergy www.dbv-technologies.com/wp-content/uploads/2019/06/dbv-t…
-
DBV Technologies reposted
KidsWithFoodAllergies
@kfatweets
Additional costs of managing #foodallergies can impact the financial health of families. Nearly 1/2 of parents reported making a career change (switch job or leave job to stay home) to care for a child with food allergies. More from KFA's recent survey: community.kidswithfoodallergies.org/blog/the-financial-im…
-
DBV Technologies reposted
Allergy & Asthma Network
@AllergyAsthmaHQ
This #foodallergyawarenessweek, take a stand against food allergy bullying, and RT to raise awareness of #noappetiteforbullying.
Join others who have pledged their support and share your story. noappetiteforbullying.com -
DBV Technologies
@DBVTechnologies
Food allergies are serious, and can be life threatening. Join us in supporting the millions of children living with food allergies by wearing teal today. RT to spread the word! #tealtakeover #foodallergyweek
-
DBV Technologies reposted
KidsWithFoodAllergies
@kfatweets
A1 Food allergies can trigger a severe reaction called anaphylaxis which can be potentially life threatening www.kidswithfoodallergies.org/page/what-is-anaphylaxis.aspx #foodallergy101
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
In honor of #foodallergyweek, join our #containscourage Campaign to help us actualize a world where everyone living with food allergies feels empowered to live free from fear and labels. Show your support by watching and sharing our “We Contain Courage” video
This media couldn't be displayed. See it on the original post. -
DBV Technologies
@DBVTechnologies
Did you know the large majority of allergic reactions are caused by 9 foods? We’re committed to raising awareness for patients and caregivers living with the daily burden of food allergy. Learn more about DBV’s mission here: dbv-technologies.com #faaw
-
DBV Technologies reposted
Allergy & Asthma Network
@AllergyAsthmaHQ
Today is the first day of #foodallergyawarenessweek! How will you bring awareness to the community around you?
Share the ways you educate about food allergies -- in your community, as an advocate, on social media. Let's raise awareness!
allergyasthmanetwork.org/education/food-allergies -
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
If you're in the #nyc area, don't forget to check out the lighting of the @EmpireStateBldg tonight. It will be shining teal in honor of #foodallergyweek
-
DBV Technologies
@DBVTechnologies
We’re excited to kick off #foodallergyweek today! At DBV, patients are at the core of everything we do. Join the conversation this week to support the food allergy community. #faaw
-
DBV Technologies
@DBVTechnologies
Thank you, @AAAAI_org, for the opportunity to present at this year’s Annual Meeting. We were pleased to share clinical and pre-clinical data from the investigational Viaskin technology platform. Learn more: www.dbv-technologies.com/wp-content/uploads/2019/02/dbv-t…
-
DBV Technologies
@DBVTechnologies
We’re presenting pre-clinical findings from the first investigational EPIT study to address #cashewallergy. If you’re at @AAAAI_org’s Annual Meeting, stop by Moscone Center South, Exhibition Level, Hall B from 9:45 –10:45 AM www.dbv-technologies.com/wp-content/uploads/2019/02/dbv-t…
-
DBV Technologies
@DBVTechnologies
Results of the first-ever Phase III trial for investigational epicutaneous immunotherapy published in @JAMA_current: jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20…
-
DBV Technologies
@DBVTechnologies
Peanut allergy management is evolving. Don’t miss Dr. Hugh Sampson join @ruchisgupta, @AllergyDocAZ & other experts for a symposium on important considerations for potential immunotherapies at @AAAAI_org’s Annual Meeting.
-
DBV Technologies
@DBVTechnologies
Thank you to all of the patients, families, physicians and research teams that contributed to the PEPITES trial, published in @JAMA_current jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20…
-
DBV Technologies
@DBVTechnologies
Attending @AAAAI_org’s Annual Meeting? Stop by booth 429 to learn about our commitment to improving the lives of those with #foodallergy via investigational epicutaneous immunotherapy.
-
DBV Technologies
@DBVTechnologies
We are pleased to announce the publication of results from the PEPITES (Peanut EPIT Efficacy and Safety) Phase III trial, evaluating the safety and efficacy of investigational Viaskin Peanut in children ages 4 to 11 in @JAMA_current: jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20…
-
DBV Technologies
@DBVTechnologies
. @AAAAI_org Annual Meeting 2019 is focused on Food Allergies; we’re looking forward to attending and presenting new data on investigational Epicutaneous Immunotherapy. www.globenewswire.com/news-release/2019/02/04/1710169/0/e…
-
DBV Technologies
@DBVTechnologies
DBV is proud to be an inaugural partner of @FoodAllergy’s Contains: Courage™ campaign, and to work with FARE to support children and families living with #foodallergies and help raise community awareness about the disease. Watch the video to learn more! www.youtube.com/watch?v=EerJUzfLVEU
-
DBV Technologies
@DBVTechnologies
Parents of children w/ #peanutallergy know how serious it can be. 69% of healthcare professionals say that the biggest challenge impacting peanut allergy management is avoidance. Sign up for tips & resources for managing peanut allergy here: talkingpeanutallergy.com
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies was proud to share additional analyses from our investigational Viaskin® Peanut Phase III clinical study with the scientific community at #acaai18 in Seattle. #foodallergies #peanutallergy www.dbv-technologies.com/wp-content/uploads/2018/11/pr-ac…
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies was thrilled to join the community at #acaai18 this year. Read more about our three oral abstracts and new clinical data analyses here. #foodallergies #peanutallergy www.dbv-technologies.com/wp-content/uploads/2018/11/pr-ac…
-
DBV Technologies
@DBVTechnologies
Stop by booth #934 at #acaai18 to learn about #dbvtechnologies and our commitment to helping improve the lives of those with #peanutallergy
-
DBV Technologies
@DBVTechnologies
Meet DBV’s new CEO, Daniel Tassé: hugin.info/156437/R/2225964/873366.pdf
-
DBV Technologies
@DBVTechnologies
We are pleased to announce that Daniel Tassé has been named CEO of DBV Technologies. Dr. Pierre-Henri Benhamou will serve as Non-Executive Chairman of the Board. Read the full announcement here: hugin.info/156437/R/2225964/873366.pdf
-
DBV Technologies
@DBVTechnologies
Attending #acaai18? Dr. Hugh Sampson will be hosting a symposium on important considerations for potential peanut allergy immunotherapies. #foodallergies #peanutallergy
-
DBV Technologies
@DBVTechnologies
Proud to be at #acaai2018 this week where DBV will present additional analyses from its investigational Viaskin® Peanut clinical program. Join us Nov. 15-19. #foodallergies #peanutallergy
-
DBV Technologies
@DBVTechnologies
Follow DBV at #acaai2018 to learn how we are building a body of scientific knowledge on peanut allergy and working to develop a therapy to address it. #foodallergies. #peanutallergy hugin.info/156437/R/2225007/872634.pdf
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies looks forward to participating at #acaai2018 next week to present research on a potential investigational treatment for #peanutallergy. Follow us for updates throughout the week. hugin.info/156437/R/2225007/872634.pdf
-
DBV Technologies
@DBVTechnologies
Join DBV Technologies at #acaai2018 on Nov. 15-19 where we will present additional data on the investigational use of epicutaneous immunotherapy for the treatment of #peanutallergy hugin.info/156437/R/2225007/872634.pdf
-
DBV Technologies
@DBVTechnologies
Being the “child with the peanut allergy” can be isolating at times. 60% of parents report added stress in their daily lives due to their child’s #peanutallergy. Learn more about how living w/ peanut allergy affects your daily life & find resources here: talkingpeanutallergy.com
-
DBV Technologies reposted
AAFA National
@AAFANational
AAFA wishes everyone a fun and safe #halloween. Double check to avoid triggers to minimize the chances of a #foodallergy reaction or asthma attack: community.aafa.org/blog/keep-kids-with-allergies-and-asth…
-
DBV Technologies reposted
Allergy & Asthma Network
@AllergyAsthmaHQ
Whether it's asthma, food allergies, latex costumes or makeup, be prepared in case you or your child develop symptoms on Halloween. www.allergyasthmanetwork.org/allergy-safe-halloween-happy…
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
Wishing everyone a HAPPY #halloween – especially those who are supporting the #tealpumpkinproject and offering non-food treats. Please feel free to share your favorite moments and pictures with us using the #tealpumpkinproject hashtag!
-
DBV Technologies
@DBVTechnologies
Halloween can be an especially stressful time for parents of children w/ #peanutallergy. Sign up for tips on how to protect your child during Halloween and beyond: talkingpeanutallergy.com
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies announces effort to enroll 400 toddlers (ages 1-3) in 35+ global clinical trial centers for Viaskin Peanut Phase III study. www.dbv-technologies.com/wp-content/uploads/2018/10/pr-ep… #foodallergies. #peanutallergy
-
DBV Technologies reposted
FABlogcon
@FABlogcon
#fablogcon 2018 is just around the corner! We’re excited to announce actress
@TiaMowry is partnering w/ @DBVTechnologies #talkingpeanutallergy campaign to share her family’s
experience with #peanutallergy – AND will be joining us at Fablogcon! Who’s excited to meet her? -
DBV Technologies
@DBVTechnologies
#dbvtechnologies announces initiation of Part B of Phase III clinical study in peanut-allergic toddlers (1-3 years old): www.dbv-technologies.com/wp-content/uploads/2018/10/pr-ep… #foodallergies. #peanutallergy
-
DBV Technologies
@DBVTechnologies
Our Talking Peanut Allergy campaign is about raising awareness of challenges faced by children w/ #peanutallergies & their families. There’s been a 21% increase in diagnoses since 2010. Join the conversation & discover new tips for managing peanut allergy: talkingpeanutallergy.com
-
DBV Technologies
@DBVTechnologies
What people with #foodallergies want you to know: Lianne Mandelbaum, @NoNotTraveler, offers a window into the heart of a food-allergic person. Read it here: themighty.com/topic/food-allergies/food-allergies-what-it…
-
DBV Technologies
@DBVTechnologies
Read real talk from real parents on raising children with #foodallergies in this thoughtful piece from @NoNutTraveler Lianne Mandelbaum.
The Mighty
@TheMightySite
"Our fears are not baseless, and neither are our precautions."
themighty.com/2018/08/food-allergy-parents/ -
DBV Technologies
@DBVTechnologies
Read the Deloitte Center for Health Solutions report about companies like #dbvtechnologies and leaders like our own Dr. Todd Green using real-world evidence to develop therapies for #peanutallergy: goo.gl/33dfD1 @DeloitteHealth
-
DBV Technologies
@DBVTechnologies
Thanks to @EAACI_HQ for another great congress! We’re already looking forward to #eaaci2019 and to sharing more research on #foodallergy from #dbvtechnologies.
-
DBV Technologies
@DBVTechnologies
#icymi: We presented 7 abstracts at #eaaci2018, including new clinical data on investigational Epicutaneous Immunotherapy #epit for #peanutallergy and #milkallergy. #foodallergy goo.gl/8iASjA
-
DBV Technologies
@DBVTechnologies
#icymi: Chief Scientific Officer Dr. Hugh Sampson moderated DBV’s symposium at #eaaci2018 about the burden of peanut allergy and its potential management. #foodallergy #research
-
DBV Technologies
@DBVTechnologies
#eaaci2018: We’re presenting clinical data on investigational Epicutaneous Immunotherapy #epit for peanut allergy. Go to Hall 13b and Poster Discussion Zone 2 from 15:45 – 17:15 CEST #research #peanutallergy
-
DBV Technologies
@DBVTechnologies
#eaaci2018: Leading allergist Dr. Bob Wood to present DBV’s late-breaking data on investigational Epicutaneous Immunotherapy for #milkallergy. Go to Hall 2 from 15:30 –17:00 CEST #research #foodallergies #clinicaltrials
-
DBV Technologies
@DBVTechnologies
Live at #eaaci2018: We’re presenting new clinical data on investigational Epicutaneous Immunotherapy #epit for #foodallergy. Join us at one of our sessions this week to learn more: www.dbv-technologies.com/wp-content/uploads/2018/05/eaaci… #peanutallergy
#milkallergy -
DBV Technologies
@DBVTechnologies
Attending #eaaci2018? Stop by Booth C11 to learn about #dbvtechnologies & our commitment to help improve the lives of those with #foodallergies and other immunological diseases. #epit
-
DBV Technologies
@DBVTechnologies
Join us at #eaaci2018 tomorrow to learn more about our new clinical data on investigational Epicutaneous Immunotherapy for #foodallergies. #milkallergy #peanutallergy #epit
-
DBV Technologies
@DBVTechnologies
Although #foodallergyweek is coming to a close, we’re working hard each day to raise awareness and develop potential options for treating food allergies #tealtakeover
-
DBV Technologies
@DBVTechnologies
We hope that food allergies can one day be treated. Innovation and new technologies can help bring us closer to that goal each day. #foodallergyweek
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies is proud to participate in #eaaci2018 next week to present our research on #foodallergy and potential new treatments. See you there!
-
DBV Technologies
@DBVTechnologies
Did you know that food allergies result in 300,000 emergency room visits for kids each year in the US? RT to help us spread the word and help prevent accidental exposure to allergens. #foodallergyweek
-
DBV Technologies
@DBVTechnologies
We are behind the entire food allergy community, including schools and educators #foodallergyweek
USDA Food and Nutrition
@USDA_FNA
Food Allergies: Helping Schools Prepare to Respond www.usda.gov/media/blog/2018/05/14/food-allergies-helping… #foodallergyweek #foodallergy
-
DBV Technologies
@DBVTechnologies
Whether you’re a parent, a healthcare provider, a teacher or working to find potential solutions, you are supporting patients with food allergies. #foodallergyweek
-
DBV Technologies
@DBVTechnologies
We’re inspired by #noappetiteforbullying this #foodallergyweek!
Allergy & Asthma Network
@AllergyAsthmaHQ
RT to raise awareness for #noappetiteforbullying during #foodallergyawarenessweek.
Many people don't understand the potentially life-threatening consequences of allergen exposure when you live with food allergies.
We can help end food allergy bullying. www.noappetiteforbullying.com -
DBV Technologies
@DBVTechnologies
We are committed to raising awareness of food allergies. We put patients at the center of all that we do. Check out these food allergy facts #foodallergyweek
-
DBV Technologies
@DBVTechnologies
We’re eager to kick off #foodallergyweek with our partner @FoodAllergy! Join us and participate in this week’s activities: www.foodallergy.org/our-initiatives/awareness-campaigns/f…
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
The iconic @EmpireStateBldg lit teal in honor of #foodallergyweek! #turnitteal #tealtakeover
-
DBV Technologies
@DBVTechnologies
We’re excited to participate in this year’s #foodallergyweek! Follow along here to see how we’re joining the conversation.
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
Drs. Hugh Sampson and Dan Adelman discuss desensitization and immunotherapy during a FARE Research Retreat plenary session moderated by Dr. Dan Rotrosen of NIAID. Great Q&A with other researchers as well as patient advocates.
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies presents data on investigational Epicutaneous Immunotherapy. Visit poster sessions this morning in the Convention Center, South Concourse, Level 1, South Hall A2 at 9:45 AM #research#foodallergy#AAAAIWAO18
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies presents Phase III topline PEPITES trial data. Go to Convention Center, SouthConcourse, Level 1, South Hall A2 at 9:45 AM #research #peanutallergy #aaaaiwao18
-
DBV Technologies
@DBVTechnologies
#aaaaiwao18 #dbvtechnologies is building relationships
within the #foodallergy community, Visit us at Booth 533 -
DBV Technologies
@DBVTechnologies
#dbvtechnologies presents data on investigational Epicutaneous Immunotherapy. Go to Convention Center, South Concourse, Level 1, South Hall A2 at 9:45 AM #research#foodallergy #aaaaiwao18
-
DBV Technologies
@DBVTechnologies
Welcome to #aaaaiwao18! #dbvtechnologies is building relationships
within the #foodallergy community, Go to booth 533 -
DBV Technologies
@DBVTechnologies
#aaaaiwao18 is here! Learn about #dbvtechnologies & our commitment to #foodallergies #peanutallergy
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies excited to participate in #aaaaiwao18 Joint Congress #peanutallergy#research#allergyawareness media.dbv-technologies.com/d286/ressources/_pdf/5/4444-AA…
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies announces results from phase II study of Viaskin Milk in milk-allergic patients #foodallergies media.dbv-technologies.com/d286/ressources/_pdf/5/4511-PR…
-
DBV Technologies
@DBVTechnologies
DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut. Read more here: media.dbv-technologies.com/d286/ressources/_pdf/5/4477-DB…
-
DBV Technologies
@DBVTechnologies
Together with @AllergyAsthmaHQ we’re providing education on avoiding cross-contact in the kitchen. Join us tomorrow! #wfc2017
-
DBV Technologies
@DBVTechnologies
#wfc2017 starts today! Join us as we discuss allergies in food service & dealing with life-threatening allergies. Hope to see you there!
-
DBV Technologies
@DBVTechnologies
Join Celebrity @ChefFalkner at the #wfc2017 “Addressing Allergies in Food Service” seminar. allergyasthmanetwork.org/wfc/
-
DBV Technologies
@DBVTechnologies
Proud to partner with @AllergyAsthmaHQ at #wfc2017. Register online until 11/8 aanma.site-ym.com/events/EventDetails.aspx?id=1015996&group=
-
DBV Technologies
@DBVTechnologies
Wishing everyone a safe Halloween tonight! Look out for Teal Pumpkins for safe and inclusive non-food treats! #tealpumpkinproject
-
DBV Technologies
@DBVTechnologies
#acaai17 might be ending, but #peanutallergy is never out of sight, out of mind. Learn more about it at livingwithpeanutallergy.com.
-
DBV Technologies
@DBVTechnologies
This Halloween, learn how you can safely participate with the #tealpumpkinproject www.foodallergy.org/resources/about-teal-pumpkin-project
-
DBV Technologies
@DBVTechnologies
#peanutallergy is never out of sight, out of mind. Stop by booth #2620 or visit livingwithpeanutallergy.com to learn more! #acaai17
-
DBV Technologies
@DBVTechnologies
Hear from Ming Tsai discussing #foodallergies in the kitchen tonight at our dinner program. You won't want to miss it! #acaai17
-
DBV Technologies
@DBVTechnologies
We are proud to sponsor the Allied Health Reception at #acaai17 and show our commitment to these important providers #immunotherapy
-
DBV Technologies
@DBVTechnologies
We're excited to see everyone at #acaai17! Stop by booth #2620 to learn more about #peanutallergy.
-
DBV Technologies
@DBVTechnologies
#dyk that accidental exposure remains a problem in #peanutallergy? Join us for dinner on 10/27 from 6:30-8:30pm #acaai17
-
DBV Technologies
@DBVTechnologies
With @FoodAllergy, we’re promoting a safer Halloween! #tealpumpkinproject Learn more: www.foodallergy.org/our-initiatives/awareness-campaigns/t…
-
DBV Technologies
@DBVTechnologies
#dyk the #tealpumpkinproject promotes safety, inclusion & respect for those managing food allergies during Halloween?
-
DBV Technologies
@DBVTechnologies
DBV Technologies Announces Topline Results of Phase III Trial in Peanut-Allergic Patients #peanutallergy media.dbv-technologies.com/d286/ressources/_pdf/5/4257-PR…
-
DBV Technologies
@DBVTechnologies
We had a great time at #eaaci2017 and enjoyed sharing our commitment to investigating treatments in #foodallergy
-
DBV Technologies
@DBVTechnologies
DBV is on a mission to find an effective, safe and patient-friendly therapy for food allergy patients! Stop by booth C.05 to learn more.
-
DBV Technologies
@DBVTechnologies
Come to the DBV booth (C.05) @ #eaaci2017 for more info on our investigations into treatment for food allergy patients
-
DBV Technologies
@DBVTechnologies
Don’t miss our symposium on investigational epicutaneous immunotherapy today, 17:45-19:15, in the Messukeskus Hall 3d #eaaci2017
-
DBV Technologies
@DBVTechnologies
Stop by our symposium tomorrow from 17:45-19:15 in Hall 3D to hear our great lineup of experts discuss investigational EPIT #eaaci2017
-
DBV Technologies
@DBVTechnologies
Join us at 15:00-15:30 in the Pro/Con Arena for our KOL Insights session on investigational epicutaneous immunotherapy #eaaci2017
-
DBV Technologies
@DBVTechnologies
As an organization committed to finding advancements in the food allergy space, DBV is proud to be at #eaaci2017
-
DBV Technologies
@DBVTechnologies
Anne Pollak, who works at DBV Technologies, understands the importance of food allergy awareness both at home & work
-
DBV Technologies
@DBVTechnologies
For Ed Jordan, working at DBV is rewarding; "our goal is to one day treat those who suffer from food allergies"#faaw
-
DBV Technologies
@DBVTechnologies
Eric Abramson, employee at DBV, knows firsthand the impact that food allergies can have on a daily basis #faaw
-
DBV Technologies
@DBVTechnologies
In honor of #faaw, Katie Falbo shares why raising awareness of food allergies is important to her #tealtakeover
-
DBV Technologies
@DBVTechnologies
#icymi: We presented 8 abstracts at #aaaai17. Learn more: media.dbv-technologies.com/d286/ressources/_pdf/5/3920-DB….
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies is presenting research on how we are advancing #immunotherapy in Hall B2 at 9:45 a.m. (Posters 801, 805 & 806) #aaaai17
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies will present data on its vaccine approach in RSV (Poster 589) at 4:45p.m. in the Thomas B. Murphy Ballroom Foyer #aaaai17
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies presents results from the OLFUS-VIPES trial on #peanutallergy at #aaaai17 media.dbv-technologies.com/d286/ressources/_pdf/5/3920-DB…
-
DBV Technologies
@DBVTechnologies
Head to Exhibit Hall B2 starting at 9:45 a.m. to see Posters 52 and 153 #aaaai17
-
DBV Technologies
@DBVTechnologies
Welcome to #aaaai17! #dbvtechnologies is building relationships within the #foodallergy community at Booth 231
-
DBV Technologies
@DBVTechnologies
#aaaai17 starts tomorrow - learn about #dbvtechnologies & our commitment to #foodallergies #peanutallergy
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies présente de nouveaux résultats 8 abstracts lors du congrès #aaaai2017 #biotech #immunotherapy media.dbv-technologies.com/d286/ressources/_pdf/5/3880-CP…
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies to present data from 8 abstracts at #aaaai2017 #biotech #immunotherapy media.dbv-technologies.com/d286/ressources/_pdf/5/3878-DB…
-
DBV Technologies reposted
Christophe Richer
@ChristRicher
Biotechnologie: ces startups #biotechs françaises qui multiplient les #innovations.
@DBVTechnologies, @adacap_news
www.lefigaro.fr/societes/2016/12/09/20005-20161209ARTFIG0… -
DBV Technologies reposted
Eric Lewin
@Eric_Lewin
Déjeuner @DBVTechnologies sans doute l'une des plus belles biotechs de Paris
-
DBV Technologies
@DBVTechnologies
DBV Completes Dosing of First Cohort in Phase I Study for Booster #vaccination Against Pertussis media.dbv-technologies.com/d286/ressources/_pdf/5/3713-PR…
-
DBV Technologies
@DBVTechnologies
Goodbye #sanfrancisco! It's been great to share and learn more about #foodallergy at #acaai
-
DBV Technologies
@DBVTechnologies
.@DBVTechnologies présentation communications scientifiques congrès #acaai16 #allergies #biotech media.dbv-technologies.com/d286/ressources/_pdf/1/3701-CP…
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies poster presentations @ACAAI reinforce our commitment to addressing the unmet need in #peanutallergy media.dbv-technologies.com/d286/ressources/_pdf/1/3700-PR…
-
DBV Technologies
@DBVTechnologies
Don't miss your opportunity to learn how #dbvtechnologies is bringing innovation to #foodallergy treatment #biotech
-
DBV Technologies
@DBVTechnologies
Are you in #sanfrancisco? Learn more about #dbvtechnologies this weekend at #acaai, booth 827
-
DBV Technologies
@DBVTechnologies
Come visit #dbvtechnologies at booth 827 #acaai #peanutallergy #biotech
-
DBV Technologies
@DBVTechnologies
We hope you'll join us tonight for an interactive scientific discussion and dinner #acaai #dbvtechnologies
-
DBV Technologies
@DBVTechnologies
Rejoignez @DBVTechnologies au congrès #acaai16 et participez à des discussions scientifiques interactives #biotech
-
DBV Technologies
@DBVTechnologies
Join #dbvtechnologies tomorrow night for an interactive scientific discussion and dinner #acaai
-
DBV Technologies
@DBVTechnologies
We are looking forward to seeing everyone at #acaai #foodallergy #dbvtechnologies
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies Announces Publication of Data From NIAID-Sponsored Phase II Academic Study in JACI #peanutallergy media.dbv-technologies.com/d286/ressources/_pdf/1/3665-PR…
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies annonce la publication des résultats d’une étude académique dans le JACI #allergiesalimentaires media.dbv-technologies.com/d286/ressources/_pdf/1/3663-CP…
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies announces topline results for the 2 year follow-up study of #peanutallergy treatment media.dbv-technologies.com/d286/ressources/_pdf/1/3654-PR…
-
DBV Technologies
@DBVTechnologies
Merci pour votre visite @axellelemaire chez @DBVTechnologies #biotech
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies Receives FDA Fast Track Designation for the Development of a Cow’s Milk Protein Allergy Treatment media.dbv-technologies.com/d286/ressources/_pdf/1/3628-PR…
-
DBV Technologies reposted
Philip Hemme
@PhilipHemme
My second interview of the week with Pierre-Henri Benhamou, the founder & CEO of @DBVTechnologies
Labiotech.eu
@Labiotech_eu
“This Phase I could Pioneer Needle-free Vaccines”, says @DBVTechnologies' CEO #peanutallergy labiotech.eu/dbv-needle-free-vaccines-phase1/?platform=ho…
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies BioNet-Asia & Geneva University Hospitals Initiate Phase I Study for Pertussis Booster Vaccination media.dbv-technologies.com/d286/ressources/_pdf/1/3583-PR…
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies to Attend Upcoming Investor Conferences in September media.dbv-technologies.com/d286/ressources/_pdf/1/3574-PR…
-
DBV Technologies
@DBVTechnologies
.@DBVTechnologies invitée à présenter lors de prochaines conférences investisseurs media.dbv-technologies.com/d286/ressources/_pdf/1/3572-CP…
-
DBV Technologies reposted
TV Finance
@TV_Finance
"DBV Technologie est aujourd’hui en partenariat avec Nestlé dans le développement d’un produit de diagnostic de l’allergie" @DBVTechnologies
-
DBV Technologies
@DBVTechnologies
Comment @DBVTechnologies a séduit EuroNext et le Nasdaq po.st/6W6yzM via @LesEchos
-
DBV Technologies
@DBVTechnologies
.@DBVTechnologies annonce la nomination de Lucia Septién en qualité de Directrice Médicale media.dbv-technologies.com/d286/ressources/_pdf/1/3450-CP…
-
DBV Technologies
@DBVTechnologies
Breaking News: @DBVTechnologies Proudly Welcomes Dr. Lucia Septién as Chief Medical Officer media.dbv-technologies.com/d286/ressources/_pdf/1/3452-PR… #biotech
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies Expands its Board of Directors @Bpifrance #biotech media.dbv-technologies.com/d286/ressources/_pdf/1/3415-PR…
-
DBV Technologies
@DBVTechnologies
Here is our latest Press Release @DBVTechnologies
media.dbv-technologies.com/d286/ressources/_pdf/1/3391-PR… #eaaci2016 #foodallergy -
DBV Technologies
@DBVTechnologies
Don't miss our Late Breaking oral session 3:45 Lehar4 @DBVTechnologies #foodallergies #biomarkers #eaaci2016
-
DBV Technologies reposted
DNAlytics
@DNAlytics
With @DBVTechnologies at @eaaci 2016 in Vienna.
-
DBV Technologies
@DBVTechnologies
Innovations on allergen-specific Immunotherapy Poster discussion @DBVTechnologies presents abstracts Right now Zone2 #foodallergy #eaaci2016
-
DBV Technologies reposted
Alize RP
@Alize_RP
Réécoutez Pierre-Henri Benhamou de @DBVTechnologies dans l'émission « L’entreprise » du 12/06 sur @bfmbusiness > www.bfmtv.com/economie/
-
DBV Technologies
@DBVTechnologies
.@DBVTechnologies Publication preclinical data #jacionline protection against #anaphylaxis media.dbv-technologies.com/d286/ressources/_pdf/1/3382-PR…
-
DBV Technologies
@DBVTechnologies
Dr Hourihane presents @DBVTechnologies symposium #foodallergies leading cause of #anaphylaxis in children #eaaci2016
-
DBV Technologies
@DBVTechnologies
Don't miss @DBVTechnologies Symposium Bringing Innovation to the treatment of #foodallergies #eaaci2016 5:30pm
-
DBV Technologies reposted
EAACI
@EAACI_HQ
M.Ebisawa is giving a talk on 'Current aspects of #foodallergy in Japan' during SYM 15 at #eaaci2016
-
DBV Technologies
@DBVTechnologies
#foodallergies From mice to men @DBVTechnologies Poster discussion Zone2 #eaaci2016
-
DBV Technologies
@DBVTechnologies
Come & attend our posters discussion @DBVTechnologies Mechanisms of Immunotherapy #eaaci2016 #foodallergies Zone3
-
DBV Technologies
@DBVTechnologies
#eaaci2016 Characterization of peanut proteins on a patch #peanutallergy Poster session @DBVTechnologies Abstract
-
DBV Technologies reposted
David Fischer, MD
@IgECPD
Hourihane: "You can't protect all of the people all of the time" when it comes to food allergy exposures in the community #eaaci2016
-
DBV Technologies reposted
Alize RP
@Alize_RP
Oral presentation immune mechanisms of allergen-specific immunotherapy - for @DBVTechnologies #eaaci2016
-
DBV Technologies
@DBVTechnologies
#eaaci2016 Oral Abstract @DBVTechnologies at 10:30 Stolz 2 Kinetics of #epigenetic & therapeutic effects
-
DBV Technologies reposted
Dr. Alberto Alvarez-Perea
@alvarezperea
What a team #allergistsgettogether #eaaci2016
-
DBV Technologies
@DBVTechnologies
Willkommen zum #eaaci2016 @DBVTechnologies präsentiert neue Daten im Bereich #foodallergy #biotech
-
DBV Technologies
@DBVTechnologies
Welcome at #eaaci2016 @DBVTechnologies presents new data #foodallergy #biotech
-
DBV Technologies reposted
EAACI
@EAACI_HQ
Safe travels to all #eaaci2016 delegates! The EAACI family is looking forward to welcoming you in #vienna!
-
DBV Technologies reposted
Jean Leymarie
@Jean_Leymarie
#allergies : le fondateur de @DBVTechnologies, Pierre-Henri Benhamou, sera l'invité de "L'Interview éco" à 18h45 sur @franceinfo #nestle
-
DBV Technologies reposted
Dr. Dario Antolin #Alergia
@DarioAntolin
Less than 1 week for the kick off #eaaci2016 !! Are you attending? This year @EAACI_HQ celebrates its 60 www.youtube.com/watch?v=DynpyxA1nY0 #allergy
-
DBV Technologies
@DBVTechnologies
SAVE THE DATE @DBVTechnologies at the #eaaci2016 June 11-15 Austria
media.dbv-technologies.com/d286/ressources/_pdf/1/3350-PR… #foodallergy #immunotherapy -
DBV Technologies reposted
Alize RP
@Alize_RP
D'ici 5 min, retrouvez Pierre-Henri BENHAMOU, CEO de @DBVTechnologies en direct de l'émission @integralebourse sur @bfmbusiness #bio2016
-
DBV Technologies reposted
BFM Business
@bfmbusiness
Nestlé détectera les allergies au lait grâce à cette biotech française ebx.sh/1P0ZclS
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies & @Nestle Health Science - A Diagnostic Test for Cow's Milk Protein Allergy media.dbv-technologies.com/d286/ressources/_pdf/1/3336-PR…
-
DBV Technologies reposted
France Biotech
@FranceBiotech
.@DBVTechnologies and @Nestle team up to develop a new diagnostic test for milk #allergies. goo.gl/KCosQm #french #biotech
-
DBV Technologies reposted
Robin Rivaton
@RobinRivaton
Bravo à @DBVTechnologies, pépite de l'Île-de-France issue de la recherche fondamentale
La Tribune
@LaTribune
Santé : Nestlé mise sur le français DBV Technologies >>www.latribune.fr/entreprises-finance/industrie/chimie-pha…
-
DBV Technologies reposted
Alize RP
@Alize_RP
.@Nestle Buys Rights to Milk-Allergy Test From French #biotech Company @DBVTechnologies > www.bloomberg.com/news/articles/2016-05-31/nestle-buys-ri… via @business #allergies
-
DBV Technologies
@DBVTechnologies
Partenariat @DBVTechnologies & @Nestlé Health Science: Test Diagnostic #allergie au Lait media.dbv-technologies.com/d286/ressources/_pdf/1/3338-CP…
-
DBV Technologies reposted
France Biotech
@FranceBiotech
@DBVTechnologies Invitée à Présenter lors des prochaines Conférences Investisseurs
www.france-biotech.org?p=28211 -
DBV Technologies reposted
Paul Field
@paul_field61
Start of #foodallergyweek with president of @AAAaust Maria Said. @TheWiggles are part of the awareness campaign
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies "championne de France des biotechs"
Alize RP
@Alize_RP
Découvrez dans vos kiosques, un article de @DBVTechnologies paru ce matin dans l’édition papier @Le_Revenu en page 4 du n°1376 #biotech
-
DBV Technologies reposted
AAAAI
@AAAAI_org
T9 Here is a video to help manage food allergies while in school. #abcdrbchat aaaai.execinc.com/videos/conditions-and-treatments/Food-A…
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
Big news! The @EmpireStateBldg is going TEAL for #foodallergyweek! RT if you're excited! www.esbnyc.com/explore/tower-lights
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies will present & host investor meetings May 2016 media.dbv-technologies.com/d286/ressources/_pdf/1/3216-PR… #biotech
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies live from the Francophone Congress of Allergology 2016 - Paris #biotech
-
DBV Technologies reposted
Alize RP
@Alize_RP
.@DBVTechnologies among the 18 of the Best European VCs for #biotech in 2016 labiotech.eu?p=24694 via @labiotech_eu #congratulations
-
DBV Technologies reposted
Allergy UK
@AllergyUK1
Our Allergy Awareness Week starts on the 25th of April - read more here: www.allergyuk.org/awareness-weeks #allergyaware
-
DBV Technologies reposted
France Biotech
@FranceBiotech
@DBVTechnologies : publication de résultats expérimentaux
www.france-biotech.org?p=27711 -
DBV Technologies
@DBVTechnologies
@DBVTechnologies epicutaneous immunotherapy induces Tregs with specific homing properties www.nature.com/cmi/articles
-
DBV Technologies reposted
FARE | Food Allergy Research & Education
@FoodAllergy
Today FARE is thrilled to host 80 scientists & stakeholders at its 4th Research Retreat. Thanks for giving us HOPE.
-
DBV Technologies reposted
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies The epicutaneous immunotherapy company committed to developing innovative treatments for severe #foodallergy #biotech
-
DBV Technologies
@DBVTechnologies
We were delighted to attend #aaaai16! See you next year! #peanutallergy #foodallergy
-
DBV Technologies reposted
Pierre-Louis Germain
@PierreLouisGerm
"Le succès des biotechs européennes"... la suite en replay.
www.tvfinance.fr/emission/direct-gestion/
Et merci @FabriceCouste @TV_Finance & @DBVTechnologies -
DBV Technologies
@DBVTechnologies
@DBVTechnologies on TV #arte Futuremag Innovation in #foodallergy: www.arte.tv/arte_vp/index.php?json_url=https%3A%2F%2Fapi.… (Subtitled in Fr Eng Germ, Sp)
-
DBV Technologies reposted
Dr. Dave Stukus
@AllergyKidsDoc
30% of kids with food allergies are bullied at school because of their food allergy. Parents, teachers, physicians need to be aware #aaaai16
-
DBV Technologies
@DBVTechnologies
.@DBVTechnologies Symposium wherever you are #aaaai16. Live webcast in 15 mn > edge.media-server.com/m/go/AAAAI2016
-
DBV Technologies
@DBVTechnologies
Press Release: Additional Phase IIb Trial Results #peanutallergy presented at the #aaaai16 by Hugh Sampson media.dbv-technologies.com/d286/ressources/_pdf/1/3063-OL…
-
DBV Technologies
@DBVTechnologies
Today at 6.00pm: @DBVTechnologies host a Symposium at #aaaai16. Live webcast at edge.media-server.com/m/go/AAAAI2016 #foodallergy
-
DBV Technologies reposted
-
DBV Technologies
@DBVTechnologies
Thank you for following @DBVTechnologies at #aaaai16
-
DBV Technologies
@DBVTechnologies
Live Poster session 417 Quantitative Assessment of safety Benefits with Peanut Thresholds & Immunotherapy #aaaai16
-
DBV Technologies
@DBVTechnologies
Poster Session N°3206 at 9:45am Poster N°417: Quantitative Assessment of the Safety Benefits #aaaai16 #foodallergy
-
DBV Technologies
@DBVTechnologies
Abst Ses N°3206 at 9:45am Poster N°437: Clinical data Phase Ib on #milkallergy treatment #aaaai16
-
DBV Technologies
@DBVTechnologies
Abst Ses N°3206 at 9:45am Poster N°415: Sustainability of Phenotype and Suppressive Activities of Tregs #aaaai16
-
DBV Technologies reposted
Dr. Dave Stukus
@AllergyKidsDoc
Accidental reaction to peanut:50% occur in homes, 3% in schools allowing peanut, 5% in schools w peanut ban #aaaai16
-
DBV Technologies reposted
-
DBV Technologies
@DBVTechnologies
Visit DBV Technologies at our Booth 313 #aaaai16
-
DBV Technologies reposted
Juan C Ivancevich MD
@Aller_MD
DBV Technologies Announces Presentation of CoFAR6 Phase II Trial Reaffirming Viaskin® Peanut Safety and Efficacy. hugin.info/156437/R/1992109/733109.pdf
-
DBV Technologies
@DBVTechnologies
Oral Session N1201 Adherence & Safety data of Peanut Patch Phase II CoFAR6
-
DBV Technologies
@DBVTechnologies
.@dbvtechnologies team will be participating in #aaaai16 on LA March 4-7. Meet us on Booth 313 #foodallergy
-
DBV Technologies
@DBVTechnologies
Academic study data on 1year safety/efficacy & biomarkers data Session N. 1201 today 10am #aaaai16 #peanutallergy
-
DBV Technologies reposted
-
DBV Technologies reposted
CFNEWS
@CFNEWStweet
#cfnewsmag Étude #biotech @lajolyA en accès libre oua.be/2926 avec @cmsbfl @Gimv @SofinnovaParis...
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies poster session/March 5 EPIT technology a broad platform. Research data on #hemophilia #aaaai16
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies Résultats Phase Ib Allergie Arachide Données Innocuité & tolérance Patch www.dbv-technologies.com/fr/relations-investisseurs/infor…
-
DBV Technologies reposted
Lianne Mandelbaum
@NoNutTraveler
What it is like in Peanut Patch Trial: My Allergic Son and I Brave Anxiety and the Unknown | Via @AllergicLiving allergicliving.com/2016/02/24/peanut-patch-trial-my-aller…
-
DBV Technologies
@DBVTechnologies
7 Trendy European Biotechs Listed on the NASDAQ in 2016 labiotech.eu?p=21171 via @labiotech_eu @DBVTechnologies
-
DBV Technologies
@DBVTechnologies
Thanks for the recent Follow @jessica_durand @nicolaschpl @GoAllergy @AmatsiGroup @mrz1125 Have all a nice weekend
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies Poster Session #aaaai16 Efficacy of EPIT® with no impact of Filaggrin Deficiency in a murine model
-
DBV Technologies
@DBVTechnologies
Cow #milkallergy @DBVTechnologies to present Phase Ib safety results #aaaai16 media.dbv-technologies.com/d286/ressources/_pdf/1/2993-PR…
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies Phase2 #peanutallergy Efficacy & Safety Data 2 year of #epicutaneous immunotherapy #aaaai16 March 6
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies Situation nette de trésorerie au 31 décembre 2015 #biotech media.dbv-technologies.com/d286/ressources/_pdf/1/3011-CP…
-
DBV Technologies
@DBVTechnologies
@DBVTechnologies We are pleased to participate #aaaai2016 March4-7 in LA to present New Data media.dbv-technologies.com/d286/ressources/_pdf/1/2993-PR…
-
DBV Technologies
@DBVTechnologies
Thanks for the recent follow @marie_dagnaud @RaquelPires85 @NoNutTraveler @SebStoizner @HortenseRomet @KristaKaroFL Have a nice Weekend
-
DBV Technologies reposted
Alize RP
@Alize_RP
Sacha Pouget, donne son avis sur le #biotech @Sachakin @DBVTechnologies @BiotechBourse > www.lerevenu.com/le-revenu-tv/les-entretiens-dexperts-de-… via @Le_Revenu
-
DBV Technologies reposted
George du Toit
@GoAllergy
@VenterCarina @MatthewBowdish see you at #aaaai2016 where some exciting new data awaits, hopefully.
-
DBV Technologies
@DBVTechnologies
#inra - Vaccin contre la bronchiolite : des avancées prometteuses pour les nourrissons www.sa.inra.fr/Toutes-les-actualites/Vaccin-contre-la-bro… INRA-@DBVTechnologies
-
DBV Technologies
@DBVTechnologies
Modifying the Immune System for Those with Food Allergies shar.es/16uIgB #dbvtechnologies
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies Crohn's Disease first experimental results Poster Presentation #aibd2015 Orlando(Florida) at 12.pm
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies at the #aibd2015 Orlando presents first experimental results on Crohn’s disease media.dbv-technologies.com/b289/ressources/_pdf/2/2698-PR…
-
DBV Technologies
@DBVTechnologies
L'avenir du vaccin passe par la peau...
Sciences et Avenir
@Sciences_Avenir
La vérité sur les vaccins >> www.sciencesetavenir.fr/sante/la-verite-sur-les-vaccins_2… Par @dominiqueleglu
-
DBV Technologies
@DBVTechnologies
Allergies alimentaires - Une immunothérapie épicutanée - Yahoo Actualités France fr.news.yahoo.com/allergies-alimentaires-immunothérapie-é… via @YahooActuFR
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies 1st Patient Enrolled In #smilee Phase IIA Study in Pediatric eosinophilic Esophagitis #foodallergy media.dbv-technologies.com/aea7/ressources/_pdf/2/2639-PR…
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies Recrutement 1er patient étude Phase IIA #smilee enfants atteints œsophagite à éosinophile media.dbv-technologies.com/aea7/ressources/_pdf/2/2641-CP…
-
DBV Technologies
@DBVTechnologies
Interview with the Co-Founder, Chairman and CEO and the COO: #dbvtechnologies S.A. (NASDAQ:DBVT) www.twst.com/interview/interview-with-the-co-founder-chai… via @wstranscript
-
DBV Technologies
@DBVTechnologies
Pierre-Henri Benhamou Pdg #dbvtechnologies au Journal de l’économie TV5 #allergiesalimentaires www.tv5mondeplus.com/video/24-10-2015/edition-du-231015-9…
-
DBV Technologies
@DBVTechnologies
Vidéo - What's Up New York: #dbvtechnologies développe un patch révolutionnaire contre l'allergie à l'arachide - www.bfmtv.com/economie/
-
DBV Technologies
@DBVTechnologies
#dbvtechnologies annonce le début du recrutement des patients allergiques au lait dans la Phase II media.dbv-technologies.com/a6bf4/ressources/_pdf/2/2332-C…
-
DBV Technologies
@DBVTechnologies
#lesechos « Le dossier du patch contre l’allergie à l’arachide de #dbvtechnologies devrait être prêt en 2017 » echo.st/b1084945
-
DBV Technologies
@DBVTechnologies
« Le dossier du patch contre l’allergie à l’arachide de DBV devrait être prêt en 2017 » echo.st/b1084945 via @InvestirFr
-
DBV Technologies
@DBVTechnologies
.@DBVTechnologies bondit après des résultats positifs via @Le_Revenu > www.lerevenu.com/bourse/valeurs-en-vue/dbv-technologies-b…
-
DBV Technologies
@DBVTechnologies
"Efficace, le patch à la cacahuète" via @le_parisien > www.leparisien.fr/espace-premium/actu/efficace-le-patch-a…













































































































































































































































































































































